



(86) Date de dépôt PCT/PCT Filing Date: 2004/06/04

(87) Date publication PCT/PCT Publication Date: 2005/02/03

(45) Date de délivrance/Issue Date: 2011/04/12

(85) Entrée phase nationale/National Entry: 2005/12/02

(86) N° demande PCT/PCT Application No.: US 2004/018202

(87) N° publication PCT/PCT Publication No.: 2005/009344

(30) Priorité/Priority: 2003/06/05 (US60/476,369)

(51) Cl.Int./Int.Cl. *C07D 231/40* (2006.01),
A61K 31/415 (2006.01), *A61K 31/4155* (2006.01),
A61K 31/4439 (2006.01), *A61P 25/28* (2006.01),
C07D 401/04 (2006.01), *C07D 401/06* (2006.01),
C07D 405/04 (2006.01), *C07D 405/12* (2006.01)

(72) Inventeurs/Inventors:


TUNG, JAY S., US;
GAROFALO, ALBERT, US;
PLEISS, MICHAEL A., US;
DRESSEN, DARREN, US;
GUINN, ASHLEY C., US;

...

(73) Propriétaire/Owner:

(54) Titre : AMINO ACIDE AMIDYLE PYRAZOLES ACYLES ET COMPOSES RELATIFS

(54) Title: ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS



Formula (I)

(57) **Abrégé/Abstract:**

This invention is directed to acylated amino acid amidyl pyrazoles and related compounds of Formula (I). The invention is also directed to a pharmaceutical formulation comprising such compound or in a pharmaceutically acceptable salt form thereof. The invention is further directed to a method for inhibiting β -amyloid peptide release and/or synthesis, a method for inhibiting γ -secretase activity, and a method for treating neurological disorders associated with β -amyloid peptide production. The method comprises administering to a host a pharmaceutical formulation comprising an effective amount of a compound of Formula (I). The compounds of Formula (I) are useful in the prevention and treatment of Alzheimer's disease. (see formula I)


(72) **Inventeurs(suite)/Inventors(continued):** JENKINS, SCOTT A., US; LATIMER, LEE H., US; SEALY, JENNIFER, US; TUCKER, JOHN, US; WONE, DAVID W. G., US; WU, JING, US

(73) **Propriétaires(suite)/Owners(continued):**ELAN PHARMACEUTICALS, INC., US

(74) **Agent:** GOWLING LAFLEUR HENDERSON LLP

Abstract

This invention is directed to acylated amino acid amidyl pyrazoles and related compounds of Formula (I). The invention is also directed to a pharmaceutical formulation comprising such compound or in a pharmaceutically acceptable salt form thereof. The invention is further directed to a method for inhibiting β -amyloid peptide release and/or synthesis, a method for inhibiting γ -secretase activity, and a method for treating neurological disorders associated with β -amyloid peptide production. The method comprises administering to a host a pharmaceutical formulation comprising an effective amount of a compound of Formula (I). The compounds of Formula (I) are useful in the prevention and treatment of Alzheimer's disease.



Formula (I)

ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS

5 FIELD OF THE INVENTION

This invention relates to acylated amino acid amidyl pyrazoles and related compounds that inhibit β -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease.

10 BACKGROUND OF THE INVENTION

Alzheimer's Disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgment and emotional stability that gradually leads to profound mental deterioration and ultimately death. AD is a very common cause of progressive mental failure (dementia) in aged humans and is believed to represent the fourth most common medical cause of death in the United States. AD has been observed in races and ethnic groups worldwide and presents a major present and future public health problem. The disease is currently estimated to affect about two to three million individuals in the United States alone. AD is at present incurable. No treatment that effectively prevents AD or reverses its symptoms and course is currently known.

20 The brains of individuals with AD exhibit characteristic lesions termed senile (or amyloid) plaques, amyloid angiopathy (amyloid deposits in blood vessels) and neurofibrillary tangles. Large numbers of these lesions, particularly amyloid plaques and neurofibrillary tangles, are generally found in several areas of the human brain important for memory and cognitive function in patients with AD. Smaller numbers of these lesions in a more restrictive anatomical distribution are also found in the brains of most aged humans who do not have clinical AD. Amyloid plaques and amyloid angiopathy also characterize the brains of individuals with Trisomy 21 (Down's Syndrome) and Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type (HCHWA-D). At present, a definitive diagnosis of AD usually requires observing the aforementioned lesions in the brain tissue of patients who have died with the disease or, rarely, in small biopsied samples of brain tissue taken during an invasive neurosurgical procedure.

The principal chemical constituent of the amyloid plaques and vascular amyloid deposits (amyloid angiopathy) characteristic of AD and the other disorders mentioned above is an approximately 4.2 kilodalton (kD) protein of about 39-43 amino acids designated the

β -amyloid peptide (β AP) or sometimes $A\beta$, $A\beta$ P or $\beta/A4$. β -Amyloid peptide was first purified and a partial amino acid sequence was provided by Glenner, *et al.* (Biochem. Biophys. Res. Commun., 120: 885-890)1984)). β -amyloid peptide is a small fragment of a much larger precursor protein (APP), normally produced by cells in tissues of various animals.


$A\beta$ is derived from cleavage of APP by protease systems, collectively termed secretases. APP is first cleaved by β secretase to yield a β stub, which is then cleaved by γ secretase to yield a β -amyloid fragment that is secreted. β secretase generates the N-terminus of $A\beta$. γ secretase generates C-terminal fragments ending at position 38, 39, 40, 42, and 43 or generating C-terminal extended precursors that are subsequently truncated to the above polypeptides.

U.S. Patent No. 6,153,652 discloses N-(aryl/heteroaryl/alkylacetyl) amino acid amides, which inhibit β amyloid peptide release and/or its synthesis, and methods for treating Alzheimer's disease with such compounds. U.S. Patent Nos. 6,191,166 and 6,211,235 each discloses a class of compounds, which inhibit β amyloid peptide release and/or its synthesis, and methods for treating Alzheimer's disease with such compounds. WO 00/38618 discloses succinoylaminobenzodiazepines and related structures and methods for inhibiting γ -secretase activity. WO 00/77030 discloses statine-derived tetrapeptide inhibitors of beta-secretase. WO 99/66934 discloses certain cyclic amino acid compounds that inhibit β -amyloid peptide release and/or its synthesis and methods for treating Alzheimer's disease with such compounds.

Despite the progress which has been made in understanding the underlying mechanisms of AD and other β -amyloid peptide related diseases, there remains a need to develop methods and compositions for treatment of the disease. The treatment methods could be based on drugs that are capable of inhibiting β -amyloid peptide release and/or its synthesis in vivo. Methods of treatment could target the formation of $A\beta$ through the enzymes involved in the proteolytic processing of β -amyloid precursor protein. Compounds that inhibit γ -secretase activity, either directly or indirectly, control the production of AP. Such inhibition of γ secretase could thereby reduce production of $A\beta$, which, thereby, reduces or prevents the neurological disorders associated with β -amyloid peptide.

SUMMARY OF THE INVENTION

This invention is directed to a class of compounds that inhibit β -amyloid peptide release and/or its synthesis. The class of compounds having the described properties are defined by formula I below:



5

Formula I


The present invention is also directed to a pharmaceutical formation comprising such compound in a pharmaceutically acceptable salt form or prodrug thereof.

The present invention is directed to a method for inhibiting β -amyloid peptide release and/or synthesis and a method for inhibiting γ -secretase activity. The present invention is also directed to a method for treating neurological disorders associated with β -amyloid peptide production. The method comprises the steps of administering to a host a pharmaceutical formulation comprising an effective amount of a compound of Formula I. The compounds of Formula I are useful in the prevention of AD in patients susceptible to AD and/or in the treatment of patients with AD.

DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to compounds that inhibit β -amyloid peptide release and/or its synthesis.


The class of compounds having the described properties is defined by Formula I below:



Formula I

or a pharmaceutically acceptable salt thereof,
 wherein R is substituted or unsubstituted aryl, cycloalkyl, heterocyclic, alkoxy,
 cycloalkoxy, aryloxy, heteroaryloxy, alkylamino, cycloalkylamino, arylamino,
 heteroarylamino; or

5 R is



wherein X' and X'' are each independently hydrogen, hydroxy or fluoro,
 provided when one of X' and X'' is fluoro, the other is not hydroxy; or

10 X' and X'' together form an oxo group,

Z is selected from the group consisting of alkyl, nitrogen, oxygen, sulfur
 and a bond covalently linking R₁ to -CX'X''-

R₁ is selected from the group consisting of hydrogen, substituted or
 unsubstituted alkyl, alkenyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, and
 15 heterocyclic;

R₂ is selected from the group consisting of hydrogen, C₁-C₄ alkyl,
 alkylalkoxy, alkylthioalkoxy, -COOR_{2a}, and -COR_{2a} wherein R_{2a} is hydrogen, C₁-4
 alkyl (such as ethyl), cycloalkyl, or heterocycle (such as pyrrolidinyl);

R₃ is H, substituted or unsubstituted, linear-, branched- or cyclo-alkyl or substituted
 20 or unsubstituted phenyl;

R₅ is -Y-R₆, wherein Y is substituted or unsubstituted alkyl, alkenyl, aryl,
 cycloalkyl, cycloalkenyl, heteroaryl, heterocyclic, or a bond; and

R₆ is substituted or unsubstituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl,
 aryloxy, heteroaryl N-oxide, or arylsulfide;


25 provided when Y is a bond, then either R₆ is cycloalkyl, or R₂ is alkylalkoxy or
 alkylthioalkoxy.

Examples of R₅ include phenylmethyl, benzhydryl, 1-phenylcyclopropyl, 1-
 phenylcyclopentyl, 1-phenylcyclohexyl, styryl, 1,1-dimethyl-1-phenylethyl, 1,1-

dimethylbutyl, 2,2-dimethyl-2-phenylethyl, 4-phenyltetrahydropyran-4-yl, 1-phenylethyl, 3-phenylpropyl, 1-methyl-1-(phenylthio)ethyl, 1-cyclohexyl-1-methylethyl, 1-methyl-4-phenylpiperidin-4-yl, 1-cyclopropyl-4-phenylpiperidin-4-yl.

- 5 A preferred R_2 is methyl. A preferred R_3 is H or t-butyl. A preferred R is (R_1 Z)CX'X", wherein said X' is H or OH, X" is H, Z is a bond, and R_1 is alkyl, substituted alkyl, aryl, or substituted aryl such as 3,5-difluorophenyl.

Preferred compounds of Formula I are shown as Formula II:



10

Formula II

- wherein R_1 is alkyl, substituted alkyl, aryl, or substituted aryl; X' is H or OH; R_2 is CH_3 ; R_3 is H, or t-butyl (with H being more preferred); Q is carbon; R_7 is aryl, substituted aryl, or U-Aryl, wherein U is O or CH_2 ; and R_8 and R_9 are independently H, or alkyl (such as CH_3), or R_8 , R_9 and Q taken together form a cycloalkyl or heterocycloalkyl.
- 15

Definition

- The term "β-amyloid peptide" refers to a 39-43 amino acid peptide having a molecular weight of about 4.2 kD, which peptide is substantially homologous to the form of the protein described by Glenner, *et al.* (*Biochem. Biophys. Res. Commun.*, 120:885-890 (1984)) including mutations and post-translational modifications of the normal β-amyloid peptide. β-amyloid peptide is approximately a 39-43 amino acid fragment of a large membrane-spanning glycoprotein, referred to as the β-amyloid precursor protein (APP). Its 43-amino acid sequence is disclosed in U.S. Patent No. 6,153,652.
- 20

- "Alkyl" refers to monovalent alkyl groups preferably having from 1 to 10 carbon atoms and more preferably 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, n-hexyl, and the like. The use of the notation "C" followed by a numerical range preceding a defined term, indicates a range of
- 25

atoms intended to add further to the definition. e.g., (C₁₋₆)alkyl defines an alkyl group having from 1 to 6 (inclusive) carbon atoms.

Unless otherwise constrained by a limitation of the alkyl group, alkyl can optionally be substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, (C₁₋₃) alkoxy, (C₁₋₃)alkylthioxy, halo, acyl, acyloxy, amino, aminoacyl, acylamino, alkoxycarbonyl, carboxyl, cyano, phenyl optionally substituted with 1 to 2 halo atoms and trifluoromethyl.

"Alkoxy" refers to the group "alkyl-O-" where alkyl is as defined herein. Preferred alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.

"Alkylalkoxy" refers to the group "-alkylene-O-alkyl," substituted or unsubstituted, which includes by way of example, methylenemethoxy (-CH₂OCH₃), ethylenemethoxy (-CH₂CH₂OCH₃), methylene-iso-propoxy (-CH₂-O-CH(CH₃)₂) and the like.

"Alkylthioalkoxy" refers to the group "-alkylene-S-alkyl," substituted or unsubstituted, which includes by way of example, methylenethiomethoxy (-CH₂SCH₃), ethylenethiomethoxy (-CH₂CH₂SCH₃), methylene-iso-thiopropoxy (-CH₂-S-CH(CH₃)₂) and the like.

"Alkenyl" refers to alkenyl groups preferably having from 2 to 10 carbon atoms and more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of alkenyl unsaturation. Preferred alkenyl groups include ethenyl (-CH=CH₂), allyl or n-2 propenyl (-CH₂CH=CH₂), iso-propenyl (-C(CH₃)=CH₂), 2-butenyl (-CH₂CH=CHCH₃) and the like.

"Alkynyl" refers to alkynyl groups preferably having from 2 to 10 carbon atoms and more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of alkynyl unsaturation. Preferred alkynyl groups include ethynyl (-C≡CH), propargyl (-CH₂-C≡CH) and the like.

"Acyl" refers to the groups alkyl-C(O)-, aryl-C(O)-, and heteroaryl-C(O)- where alkyl, aryl and heteroaryl are as defined herein.

"Acylamino" refers to the group -C(O)NRR where each R is independently hydrogen or alkyl where alkyl is as defined herein.

"Aminoacyl" refers to the group -NRC(O)R where each R is independently hydrogen or alkyl where alkyl is as defined herein.

"Acyloxy" refers to the groups alkyl-C(O)O-, aryl-C(O)O-, heteroaryl-C(O)O-, and heterocyclic-C(O)O- where alkyl, aryl, heteroaryl and heterocyclic are as defined herein.

"Aryl" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl). Preferred aryls include phenyl, naphthyl and the like.

"Arylalkyl" refers to aryl -alkyl- groups preferably having from 1 to 6 carbon atoms in the alkyl moiety and from 6 to 10 carbon atoms in the aryl moiety. Such arylalkyl groups are exemplified by benzyl, phenethyl and the like.

"Arylalkenyl" refers to aryl -alkenyl- groups preferably having from 1 to 6 carbon atoms in the alkenyl moiety and from 6 to 10 carbon atoms in the aryl moiety.

"Arylalkynyl" refers to aryl -alkynyl- groups preferably having from 1 to 6 carbon atoms in the alkynyl moiety and from 6 to 10 carbon atoms in the aryl moiety.

"Aryloxy" refers to the group aryl-O- wherein the aryl group is as defined above including optionally substituted aryl groups as also defined above.

The terms "amide" and "amido" refer to a functional group containing a carbon atom double-bonded to an oxygen atom and additionally singly bonded to a nitrogen atom [-C(O)-N]. "Primary" amide describes an unsubstituted amide group [-C(O)-NH₂]. "Secondary" and "tertiary" amides are amides in which nitrogen is substituted with one and two non-hydrogen groups respectively.

"Cycloalkyl" refers to cyclic alkyl groups of from 3 to 10 carbon atoms having a single cyclic ring or multiple condensed rings which can be optionally substituted with from 1 to 3 alkyl groups. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, and the like, or multiple ring structures such as adamantyl, and the like.

"Cycloalkenyl" refers to cyclic alkenyl groups of from 4 to 8 carbon atoms having a single cyclic ring and at least one point of internal unsaturation which can be optionally substituted with from 1 to 3 alkyl groups. Examples of suitable cycloalkenyl groups include, for instance, cyclobut-2-enyl, cyclopent-3-enyl, cyclooct-3-enyl and the like.

"Halo" or "halogen" refers to fluoro, chloro, bromo and iodo and preferably is either chloro or fluoro.

"Heteroaryl" refers to a monovalent aromatic carbocyclic group of from 1 to 10 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur within the

ring. Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl).

"Heterocycle" or "heterocyclic" refers to a saturated or unsaturated group having a single ring or multiple condensed rings, from 1 to 8 carbon atoms and from 1 to 4 hetero
5 atoms selected from nitrogen, sulfur or oxygen within the ring. Such heterocyclic groups can have a single ring (e.g., piperidinyl or tetrahydrofuryl) or multiple condensed rings (e.g., indolinyl, dihydrobenzofuran or quinuclidinyl). Preferred heterocycles include piperidinyl, pyrrolidinyl and tetrahydrofuryl.

Examples of heterocycles and heteroaryls include, but are not limited to, furan,
10 thiophene, thiazole, oxazole, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine,
15 pyrrolidine, indoline and the like.

"Thiol" refers to the group -SH.

"Thioalkoxy" refers to the group -S-alkyl.

"Thioaryloxy" refers to the group aryl-S- wherein the aryl group is as defined above including optionally substituted aryl groups as also defined above.

Unless otherwise constrained by the definition for the individual substituent, aryl,
20 cycloalkyl, heteroaryl, and heterocyclic groups can be optionally substituted with 1 to 3 substituents selected from the group consisting of alkyl, alkenyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclic, alkaryl, alkycycloalkyl, alkycycloalkenyl, alkheteroaryl, alkheterocyclic, alkoxy, aryloxy, halo, nitro, hydroxy, amino, acyl, acyloxy, aminoacyl,
25 acylamino, carboxy, cyano, alkoxycarbonyl, thioalkoxy, thioaryloxy and the like. Preferred substituents include alkyl, alkoxy, halo, cyano, nitro, hydroxy, trihalomethyl, thioalkoxy, and amino.

"Pharmaceutically acceptable salt" refers to pharmaceutically acceptable salts of a compound of Formula I which salts are derived from a variety of organic and inorganic
30 counter ions well known in the art and include, by way of example only, lithium, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.

Pharmaceutical Formulations

When employed as pharmaceuticals, the compounds of Formula I are usually administered in the form of pharmaceutical compositions. These compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These compounds are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.

This invention also includes pharmaceutical compositions that contain, as the active ingredient, one or more of the compounds of Formula I, or a pharmaceutically accepted form or prodrug thereof, associated with pharmaceutically acceptable carriers. In making the compositions of this invention, the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide

quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

The compositions are preferably formulated in a unit dosage form, each dosage containing from about 1 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Preferably, the compound of formula I above is employed at no more than about 20 weight percent of the pharmaceutical composition, more preferably no more than about 15 weight percent, with the balance being pharmaceutically inert carriers.

The active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. The amount of the compound actually administered will be determined by a physician, in view of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention.

The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number

of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

The liquid forms in which the novel compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably
5 flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as corn oil, cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
10 The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may
15 be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

Another preferred formulation employed in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to
20 provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. No. 5,023,252.

Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

25 Often, it is desirable or necessary to introduce the pharmaceutical composition to the brain, either directly or indirectly. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. One such implantable delivery system used for the transport of biological factors to specific anatomical regions of the body is described in U.S. Pat. No. 5,011,472.

30

Indirect techniques, which are generally preferred, usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs. Latentiation is generally achieved through blocking of the hydroxy,

carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.

5 Other suitable formulations for use in the present invention can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, Pa., 17th ed. (1985).

Utility

10 The present invention is directed to a method for inhibiting β -amyloid peptide release and/or synthesis in a cell and a method for inhibiting γ -secretase activity. The invention is also directed to a method for preventing or treating of neurological disorders associated with β -amyloid peptide production. The method comprises the steps of administering to a host in need of such treatment a pharmaceutical formulation comprising a
15 therapeutically effective amount of a compound of Formula I. The compounds of Formula I are useful in the prevention of AD in patients susceptible to AD and/or in the treatment of patients with AD.

$A\beta$ production has been implicated in the pathology of Alzheimer's Disease (AD). The compounds of the present invention have utility for the prevention and treatment of AD
20 by inhibiting $A\beta$ production. Methods of treatment target formation of $A\beta$ production through the enzymes involved in the proteolytic processing of β -amyloid precursor protein. Compounds that inhibit γ secretase activity, either directly or indirectly, control the production of $A\beta$. Such inhibition of γ secretase reduces production of $A\beta$, and is expected to reduce or prevent the neurological disorders associated with $A\beta$, such as Alzheimer's
25 Disease.

 Compounds of Formula I are expected to possess γ -secretase inhibitory activity or inhibit $A\beta$ production. Cellular screening methods for inhibitors of $A\beta$ production, testing methods for the *in vivo* suppression of $A\beta$ production, and assays for the detection of secretase activity are known in the art and have been disclosed in many publications,
30 including WO 98/22493 and WO 01/19797, EP 0652009, U.S. Patent Nos. 5,703,129 5,593,846; 6,211,235 and 6,207,710.

Compounds provided by this invention are useful as standards and reagents in determining the ability of a potential pharmaceutical reagent to inhibit A β production. These can be provided in a kit comprising a compound of this invention.

A compound is considered to be active if it has an IC₅₀ or K_i value of less than about
5 100 μ M for the inhibition of A β production.

Synthesis and Preparation of Compounds Having Formula I


The compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis. The compounds of the present invention can
10 be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.

The novel compounds of this invention may be prepared using the reactions and
15 techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the
20 conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods
25 must then be used.


Construction of Acylated Amino Acid Amidyl pyrazoles.

A variety of substituted acylated amino acid amidyl pyrazoles can be prepared using the corresponding carboxylic acids in this fashion. The following Methods A-f show
30 general methods for preparing acylated amino acid amidyl pyrazoles.

Synthesis of pyrazoles (type 8 and 9).




A variety of 5' substituted pyrazoles can be prepared using carboxylic acid (1), amino acids (4, natural and unnatural) and an additional carboxylic acid (7). In some instances, protecting group strategies on R, R₂ and/or R₅ are required, the methods described in Protective Groups In Organic Synthesis (Theodora W. Greene and Peter G. M. Wuts, Wiley and Sons) were employed to address these cases.




METHOD A

In a dried round bottom flask, a solution of carboxylic acid 1 is prepared. To the reaction solution, N,N'-carbonyldiimidazole is added. In a separate round bottom flask, a solution of cyanoacetic acid is added with isopropylmagnesium chloride. The two reaction mixtures are mixed together and after a time sufficient for reaction, combined with acetic acid to bring to ~pH 5. The crude material is further processed to give a yellowish oil as ketonitrile product 2.



METHOD B


A solution of ketonitrile **2**, *tert*-butylhydrazine, and triethylamine in absolute ethanol is refluxed for a time sufficient for reaction to proceed. After cooling to room temperature, the reaction solution is concentrated, extracted with EtOAc, and dried. The residual crude material is flash chromatographed to afford the *t*-butyl amino pyrazole **3**.



METHOD C

General Procedure for POCl₃ Coupling of *t*-butyl amino pyrazole **3** with amino acid **4**.


A solution of **3** and amino acid **4** in suitable solvent is added with POCl₃. The reaction mixture is then extracted, dried, and the solvent removed. Purification of the material affords product **5**.



METHOD D

15

A solution of *N*-*tert*-butyl protected pyrazole **5** is stirred in a solution of methylene chloride/trifluoroacetic acid. The volatiles are evaporated off to yield the corresponding salt of the desired amine **6**.




20

METHOD E


The carboxylic acid **7**, amine **6**, triethylamine (TEA) and hydroxybenzotriazole hydrate (HOBT) are mixed. The mixture is then added with 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (EDCI). The reaction mixture is then

5 purified to yield the desired product **8**.



METHOD F

- 10 A solution of N-*tert*-butyl protected pyrazole **8** in formic acid is refluxed then added to saturated $\text{NaHCO}_3(\text{aq})$. The quenched solution is extracted, dried, and vacuum filtered. The crude material is chromatographed on silica to give the *t*-butyl deprotected product **9**. In the event that functionalities on R, R_2 or R_5 have been formylated as a result of Method F, the resulting formyl group is removed.




15

20

EXAMPLES

Examples A-H show methods for preparing acylted amino acid amidyl pyrazoles.



A. CDI, THF then NCCH₂CO₂H, *i*-PrMgCl, THF B. *t*-BuNHNH₂•HCl, Et₃N, EtOH C. Cbz-Ala-OH, POCl₃, pyridine D. TFA E. CH₂O, NaOAc, NaCNBH₃, MeOH F. 10% Pd/C, EtOH, H₂ G. 3,5-difluoromandelic acid, EDC•HCl, HOBT, NMM, THF H. TFA.

Example A.

4-(2-Cyanoacetyl)-4-phenylpiperidine-1-carboxylic acid *tert*-butyl ester. A solution of 2.52 g (30 mmol) of cyanoacetic acid in 80 mL of dry THF was stirred at -78 °C as 24.6 mL (49.2 mmol) of 2.0 M *i*-PrMgCl in THF was added. After 1 h, a solution of 3.00 g (10 mmol) 1-*tert*-butoxycarbonyl-4-phenylpiperidine-4-carboxylic acid (Maybridge, cat. no. JFD 01929) and 1.93 g (12 mmol) of 1,1'-carbonyldiimidazole in 20 mL of THF was added. The reaction mixture was allowed to warm to rt. After 16 h, the mixture was poured into 300 mL of water and the pH lowered to 4 with conc. AcOH. The mixture was then extracted with EtOAc, dried over MgSO₄ and concentrated. Purification on silica gel using 1:1 EtOAc-hexanes as eluant afforded 4-(2-cyanoacetyl)-4-phenylpiperidine-1-carboxylic acid *tert*-butyl ester.

Example B.

4-(5-Amino-1-*tert*-butyl-1*H*-pyrazol-3-yl)-4-phenylpiperidine-1-carboxylic acid *tert*-butyl ester. A solution of 1.66 g (5.0 mmol) of 4-(2-cyanoacetyl)-4-phenylpiperidine-1-carboxylic acid *tert*-butyl ester, 2.20 mL (16 mmol) of Et₃N and 2.00 g (16 mmol) of *tert*-butylhydrazine hydrochloride in 20 mL of absolute EtOH was heated to 100 °C in a sealed tube. After 64 h, the reaction mixture was cooled to rt and concentrated. Purification on silica gel using 30:70 EtOAc-hexanes as eluant afforded 4-(5-amino-1-*tert*-butyl-1*H*-pyrazol-3-yl)-4-phenylpiperidine-1-carboxylic acid *tert*-butyl ester.

Example C.

4-[5-(2-Benzylloxycarbonylamino-propionylamino)-1-*tert*-butyl-1*H*-pyrazol-3-yl]-4-phenylpiperidine-1-carboxylic acid *tert*-butyl ester. A solution of 0.68 g (1.7 mmol) of 4-(5-amino-1-*tert*-butyl-1*H*-pyrazol-3-yl)-4-phenylpiperidine-1-carboxylic acid *tert*-butyl ester and 0.39 g (1.7 mmol) of carbobenzyloxy-L-alanine in 9.0 mL of dry pyridine was stirred at -10 °C as 0.18 mL (1.9 mmol) of POCl₃ was added. After 25 min, the reaction mixture was poured into 1M HCl and extracted with EtOAc. The organic layer was washed with sat. aq. NaHCO₃, dried over MgSO₄ and concentrated. Purification on silica gel using 50:50 EtOAc-hexanes as eluant afforded 4-[5-(2-benzylloxycarbonylamino-propionylamino)-1-*tert*-butyl-1*H*-pyrazol-3-yl]-4-phenylpiperidine-1-carboxylic acid *tert*-butyl ester.

Example D.

{1-[2-*tert*-Butyl-5-(4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-ylcarbamoyl]ethyl}carbamic acid benzyl ester. A solution of 0.54 g (0.9 mmol) of 4-[5-(2-benzylloxycarbonylamino-propionylamino)-1-*tert*-butyl-1*H*-pyrazol-3-yl]-4-phenylpiperidine-1-carboxylic acid *tert*-butyl ester in 4.0 mL of neat trifluoroacetic acid was stirred at rt for 15 min. The reaction mixture was then poured into sat. aq. NaHCO₃ and extracted with EtOAc. The organic layer was dried over MgSO₄ and concentrated to afford {1-[2-*tert*-butyl-5-(4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-ylcarbamoyl]ethyl}-carbamic acid benzyl ester which was used without further purification.

Example E.

{1-[2-*tert*-Butyl-5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-ylcarbamoyl]ethyl}carbamic acid benzyl ester. A solution of 0.67 g (1.3 mmol) of {1-[2-*tert*-butyl-5-(4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-ylcarbamoyl]ethyl}carbamic acid benzyl ester, 0.33 mL (4.0 mmol) of 37% aq. formaldehyde, 0.33 g (4.0 mmol) of NaOAc and 0.27 g (4.3 mmol) of NaCNBH₃ in 10 mL of MeOH was stirred at rt. After 16 h, the reaction mixture was concentrated and extracted with water and EtOAc. The organic layer was dried over MgSO₄, and concentrated. Purification on silica gel using 4% Et₃N-MeOH as eluant afforded {1-[2-*tert*-butyl-5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-ylcarbamoyl]ethyl}carbamic acid benzyl ester.

Example F.

15

2-Amino-*N*-[2-*tert*-butyl-5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-yl]propionamide. A suspension of 0.36 g (0.7 mmol) of {1-[2-*tert*-butyl-5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-ylcarbamoyl]ethyl}carbamic acid benzyl ester and 0.36 g of 10% Pd/C in 5.0 mL of absolute EtOH was agitated under 30 psi H₂ for 16 h. The reaction mixture was filtered through Celite™ and 0.36 g of fresh 10% Pd/C was added to the filtrate which was again agitated under 30 psi H₂ for 16 h. This process was repeated once more and, after a final filtration, the filtrate was concentrated. Purification on silica gel using 4% Et₃N-MeOH as eluant afforded 2-amino-*N*-[2-*tert*-butyl-5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-yl]propionamide.

25


Example G.

***N*-[2-*tert*-Butyl-5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-yl]-2-[2-(3,5-difluorophenyl)-2-hydroxyacetyl-amino]propionamide.** A solution of 0.14 g (0.4 mmol) of 2-amino-*N*-[2-*tert*-butyl-5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-yl]propionamide and 0.08 g (0.4 mmol) of (*S*)-3,5-difluoromandelic acid (Garofalo, et al. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 3051) in 5.0 mL of THF was stirred at rt as 0.06 g (0.4 mmol) of HOBT and 0.08 mL (0.7 mmol) of NMM was added followed by 0.90 g (0.5 mmol) of EDC•HCl. After 16 h, the reaction was quenched with 1M HCl and extracted with EtOAc. The organic layer was washed with sat. aq. NaHCO₃, dried over MgSO₄ and concentrated. Purification on silica gel using 4% Et₃N-MeOH as eluant afforded *N*-[2-*tert*-butyl-5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-yl]-2-[2-(3,5-difluorophenyl)-2-hydroxyacetyl-amino]propionamide.

Example H.

2-[2-(3,5-Difluorophenyl)-2-hydroxyacetyl-amino]-*N*-[5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-yl]propionamide. A solution of 0.04 g (0.1 mmol) of *N*-[2-*tert*-butyl-5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-yl]-2-[2-(3,5-difluorophenyl)-2-hydroxyacetyl-amino]propionamide in 2.0 mL of neat trifluoroacetic acid was refluxed for 15 min. The reaction mixture was then cooled to rt, quenched with sat. aq. NaHCO₃ and extracted with EtOAc. The organic layer was dried over Na₂SO₄ and concentrated. Purification on silica gel afforded 2-[2-(3,5-difluorophenyl)-2-hydroxyacetyl-amino]-*N*-[5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-yl]propionamide.

Methods A-E or A-F were utilized to prepared the following compounds (Examples 1-107).


Example 1.

MS 415.0 (M+H), 436.8 (M+Na), 452.6 (M+K).

Anal Calcd for $C_{21}H_{20}F_2N_4O_3$: C, 60.87; H, 4.86; N, 13.52. Found: C, 60.73; H, 4.73; N, 13.28.

- 5 ^1H NMR ($CDCl_3$, 300 MHz) δ 11.97 (s, 1H), 7.99 (d, $J = 9.3$ Hz, 1H), 7.21 (m, 5H), 7.09 (d, $J = 6.1$ Hz, 2H), 6.79 (m, 1H), 6.37 (s, 1H), 5.11 (s, 1H), 4.74 (m, 1H), 3.85 (m, 2H), 1.35 (d, $J = 6.6$ Hz, 3H).

Example 2.




MS 415.2 (M+H), 436.8 (M+Na).

Anal Calcd for $C_{21}H_{20}F_2N_4O_3 \cdot 1/4H_2O$: C, 60.21; H, 4.93; N, 13.57. Found: C, 60.24; H, 4.76; N, 13.31.

- 15 ^1H NMR ($CDCl_3$, 300 MHz) δ 11.82 (s, 1H), 8.03 (d, $J = 9.3$ Hz, 1H), 7.23 (m, 5H), 6.95 (d, $J = 6.0$ Hz, 2H), 6.57 (m, 1H), 6.21 (s, 1H), 5.16 (s, 1H), 4.87 (m, 1H), 3.84 (m, 2H), 1.41 (d, $J = 6.6$ Hz, 3H).


Example 3.



MS 440.8 (M+H), 463.2 (M+Na).

Anal Calcd for $C_{23}H_{22}F_2N_4O_3$: C, 62.72; H, 5.03; N, 12.72. Found: C, 62.69; H, 5.03; N, 12.68.


- 25 ^1H NMR ($CDCl_3$, 300 MHz) δ 11.55 (s, 1H), 11.33 (s(br), 1H), 7.70 (d, $J = 9.9$ Hz, 1H), 7.23 (m, 5H), 7.04 (d, $J = 7.1$ Hz, 2H), 6.76 (t, $J = 8.2$ Hz, 1H), 6.30 (s, 1H), 5.39 (s(br), 1H), 4.71 (m, 1H), 1.33 (m, 7H).

Example 4.

5 MS 469.3 (M+H), 491.3 (M+Na).

Anal Calcd for $C_{25}H_{26}F_2N_4O_3$: C, 64.09; H, 5.59; N, 11.96. Found: C, 64.06; H, 5.52; N, 11.66.


^1H NMR ($CDCl_3$, 300 MHz) δ 12.01 (s, 1H), 11.75 (s(br), 1H), 7.84 (d, $J = 9.3$ Hz, 1H), 7.18 (m, 7H), 6.81 (t, $J = 8.8$ Hz, 1H), 6.43 (s, 1H), 5.95 (s(br), 1H), 5.14 (s, 1H), 4.73 (m, 1H), 2.35 (m, 2H), 2.14 (m, 2H), 1.65 (m, 4H), 1.41 (d, $J = 6.6$ Hz, 3H).

Example 5.

15 MS 477.0 (M+H).

Anal Calcd for $C_{23}H_{23}ClF_2N_4O_3$: C, 57.93; H, 4.86; N, 11.75. Found: C, 57.68; H, 4.92; N, 11.83.

^1H NMR ($CDCl_3$, 300 MHz) δ 11.75 (s(br), 1H), 7.75 (d, $J = 9.3$ Hz, 1H), 7.16 (m, 4H), 7.02 (d, $J = 6.0$ Hz, 2H), 6.77 (t, $J = 8.8$ Hz, 1H), 6.50 (s, 1H), 5.08 (s, 1H), 4.74 (m, 1H), 1.64 (s, 6H), 1.43 (d, $J = 6.6$ Hz, 3H).

Example 6.


25

MS 488.3 (M+H), 510.1 (M+Na).

Anal Calcd for $C_{23}H_{23}F_2N_5O_5 \cdot H_2O$: C, 55.64; H, 4.87; N, 14.11. Found: C, 55.60; H, 4.82; N, 13.88.

^1H NMR (CDCl_3 , 300 MHz) δ 12.14 (s(br), 1H), 12.03 (s(br), 1H), 8.04 (d, $J = 8.9$, 2H), 7.95 (d, $J = 8.2$ Hz, 1H), 7.33 (d, $J = 8.8$ Hz, 2H), 7.01 (d, $J = 6.0$ Hz, 2H), 6.77 (m, 1H), 5.98 (s(br), 1H), 5.11 (s, 1H), 4.74 (m, 1H), 1.68 (s, 3H), 1.66 (s, 3H), 1.44 (d, $J = 6.6$ Hz, 3H).


5

Example 7.

MS 505.3 (M+H), 527.1 (M+Na).

10 Anal Calcd for $\text{C}_{28}\text{H}_{26}\text{F}_2\text{N}_4\text{O}_3 \cdot 3/4\text{H}_2\text{O}$: C, 64.92; H, 5.35; N, 10.81. Found: C, 64.94; H, 5.24; N, 10.81.


^1H NMR (CD_3OD , 300 MHz) δ 7.24 (m, 6H), 7.09 (m, 6H), 6.83 (m, 1H), 6.13 (s, 1H), 5.04 (s, 1H), 4.46 (m, 1H), 2.10 (s, 3H), 1.36 (d, $J = 7.14$, 3H).

15 **Example 8.**

MS 491.1 (M+H), 513.1 (M+Na).

Anal Calcd for $\text{C}_{27}\text{H}_{24}\text{F}_2\text{N}_4\text{O}_3$: C, 66.11; H, 4.93; N, 11.42. Found: C, 65.79; H, 5.22; N, 11.25.

20 ^1H NMR (CDCl_3 , 300 MHz) δ 7.74 (d, $J = 9.3$ Hz, 1H), 7.21 (m, 10H), 6.89 (d, $J = 6.0$ Hz, 2H), 6.73 (m, 1H), 6.38 (s, 1H), 5.44 (s, 1H), 4.91 (s, 1H), 4.68 (m, 1H), 1.33 (d, $J = 7.1$ Hz, 3H).

25 **Example 9.**


MS 427.2 (M+H), 449.2 (M+Na).

Anal Calcd for $C_{22}H_{20}F_2N_4O_3 \cdot 3/4H_2O$: C, 60.06; H, 4.93; N, 12.74. Found: C, 60.27; H, 4.80; N, 12.83.

- 5 ^1H NMR ($CDCl_3$, 300 MHz) δ 12.10 (s, 1H), 7.91 (d, $J = 9.9$ Hz, 1H), 7.32 (m, 5H), 7.17 (d, $J = 6.0$ Hz, 2H), 7.00 (d, $J = 7.0$ Hz, 1H), 6.72 (m, 2H), 6.62 (s, 1H), 5.67 (s(br), 1H), 5.20 (s, 1H), 4.87 (m, 1H), 1.44 (d, $J = 6.6$ Hz, 3H).

Example 10.

10




- 15 A solution of 90480 (0.74 mmole) in 15 mL of absolute EtOH was prepared. To the solution, was added 0.32 g of 10% Pd on carbon. The reaction mixture was stirred under a balloon of H_2 for 1 hr. The reaction mixture was filtered through a bed of celiteTM on a fritted filter. The filtrate was concentrated by rotary evaporation. The crude material was flash chromatographed on silica using 10% MeOH/ CH_2Cl_2 as eluant to afford the reduced product 90603 (70%).

- 20 MS 457.9 (M+H), 479.5 (M+Na).

Anal Calcd for $C_{23}H_{25}F_2N_5O_3 \cdot 5/4H_2O$: C, 57.55; H, 5.77; N, 14.59. Found: C, 57.33; H, 5.41; N, 14.26.

- ^1H NMR ($CDCl_3$, 300 MHz) δ 11.81 (s, 1H), 7.84 (d, $J = 9.3$ Hz, 1H), 6.95 (m, 2H), 6.71 (m, 1H), 6.53 (m, 3H), 5.80 (s(br), 1H), 4.74 (m, 2H), 3.68 (s(br), 1H), 1.61 (s, 3H), 1.57 (s, 3H), 1.36 (d, $J = 6.6$ Hz, 3H).
- 25

Example 11.




A solution of 0.21 mmole (1.0 eq.) of 90603 in 1 mL of pyridine was prepared. To the solution, was added 0.53 mmole (2.5 eq.) of acetic anhydride. After stirring the solution for 3.5 days at rt, it was poured into 25 mL of 2 M HCl. The solution was extracted with EtOAc (3 X 40 mL). The combined organic layers were dried over Na₂SO₄ and vacuum
5 filtered. The filtrate was rotary evaporated. The residual solid was dissolved in 5 mL of MeOH and 0.33 mmole (2 eq.) of LiOH was added to remove undesired acylation of the hydroxyl group. The mixture was stirred at rt for 20 min and rotary evaporated. The solid was dissolved in 15 mL of H₂O. The aqueous layer was extracted with EtOAc (3 X 40 mL). The combined organic extracts were dried over Na₂SO₄ and vacuum filtered. The
10 filtrate was rotary evaporated. The crude material was flash chromatographed on silica using 10% MeOH/CH₂Cl₂ as eluant to give acylated product 91493 (50%).

MS 499.5 (M+H), 521.3 (M+Na).

Anal Calcd for C₂₅H₂₇F₂N₅O₄•3/2H₂O: C, 57.03; H, 5.74; N, 13.30. Found: C, 57.03; H,
15 5.41; N, 12.98.

¹H NMR (CD₃OD, 300 MHz) δ 7.74 (d, *J* = 6.6 Hz, 2H), 7.22 (d, *J* = 6.6 Hz, 2H), 7.14 (d, *J* = 7.1 Hz, 2H), 6.90 (m, 1H), 6.46 (s(br), 1H), 5.11 (s, 1H), 4.55 (m, 1H), 2.12 (m, 3H), 1.70 (s, 6H), 1.44 (d, *J* = 5.5 Hz, 3H).


20 Example 12.



MS 487.3 (M+H), 509.3 (M+Na).

25 Anal Calcd for C₂₅H₂₅F₃N₄O₃: C, 61.72; H, 5.18; N, 11.52. Found: C, 61.89; H, 5.43; N, 11.14.


¹H NMR (CDCl₃, 300 MHz) δ 12.11 (s, 1H), 11.84 (s(br), 1H), 7.87 (d, *J* = 9.9 Hz, 1H), 7.16 (m, 4H), 6.82 (m, 3H), 6.39 (s, 1H), 5.99 (s(br), 1H), 5.15 (s, 1H), 4.74 (m, 1H), 2.31 (m, 2H), 2.09 (m, 2H), 1.71 (m, 4H), 1.43 (d, *J* = 6.6 Hz, 3H).

Example 13.


5 MS 503.1 (M+H), 525.1 (M+Na).

Anal Calcd for $C_{25}H_{25}F_2ClN_4O_3 \cdot 11/10H_2O$: C, 57.44; H, 5.24; N, 10.72. Found: C, 57.79; H, 5.04; N, 10.32.

^1H NMR ($CDCl_3$, 300 MHz) δ 12.12 (s, 1H), 11.88 (s(br), 1H), 7.90 (d, $J = 9.9$ Hz, 1H), 6.82 (m, 1H), 6.40 (s, 1H), 6.07 (s(br), 1H), 5.17 (s, 1H), 4.74 (m, 1H), 2.33 (m, 2H), 2.08 (m, 2H), 1.68 (m, 4H), 1.44 (d, $J = 6.6$ Hz, 3H).

Example 14.


15 ^1H NMR ($CDCl_3$, 300 MHz) δ 11.71 (s, 1H), 7.79 (d, $J = 9.3$ Hz, 1H), 7.21 (m, 5H), 7.06 (d, $J = 6.6$ Hz, 2H), 6.77 (m, 1H), 6.43 (s, 1H), 5.11 (s, 1H), 4.71 (m, 1H), 1.58 (d, $J = 6.6$ Hz, 3H), 1.39 (d, $J = 6.6$ Hz, 3H).

Example 15.

MS 483.3 (M+H), 505.3 (M+Na), 521.3 (M+K).

25 Anal Calcd for $C_{26}H_{28}F_2N_4O_3 \cdot 5/4H_2O$: C, 61.83; H, 6.09; N, 11.09. Found: C, 62.10; H, 5.97; N, 10.76.

^1H NMR ($CDCl_3$, 300 MHz) δ 12.06 (s, 1H), 11.75 (s(br), 1H), 7.83 (d, $J = 9.9$ Hz, 1H), 7.24 (m, 5H), 7.20 (d, $J = 6.6$ Hz, 2H), 6.79 (m, 1H), 6.44 (s, 1H), 5.84 (s(br), 1H), 5.11 (s, 1H), 4.76 (m, 1H), 2.17 (m, 4H), 1.51 (m, 9H).

Example 16.


5

MS 486.5 (M+H), 508.5 (M+Na).

Anal Calcd for C₂₅H₂₅F₃N₄O₃: C, 61.72; H, 5.18; N, 11.52. Found: C, 61.45; H, 5.26; N, 11.41.

¹H NMR (CDCl₃, 300 MHz) δ 11.51 (s(br), 1H), 7.60 (m, 1H), 7.34 (m, 1H), 7.06 (m, 4H), 6.90 (m, 1H), 6.79 (m, 1H), 6.47 (s, 1H), 5.12 (s, 1H), 4.73 (m, 1H), 2.52 (m, 2H), 2.17 (m, 2H), 1.80 (m, 4H), 1.39 (d, *J* = 6.6 Hz, 3H).

10

Example 17.


15

MS 461.0 (M+H), 482.2 (M+Na).

Anal Calcd for C₂₃H₂₃F₃N₄O₃: C, 59.99; H, 5.03; N, 12.17. Found: C, 60.08; H, 5.11; N, 11.96.

¹H NMR (CD₃OD, 300 MHz) δ 7.31 (m, 2H), 7.15 (m, 3H), 7.03 (m, 1H), 6.89 (m, 1H), 6.38 (s(br), 1H), 5.12 (s, 1H), 4.57 (m, 1H), 1.76 (s, 6H), 1.44 (d, *J* = 7.1 Hz, 3H).

20

Example 18.

25


MS 471.4 (M+H), 493.2 (M+Na).

Anal Calcd for $C_{25}H_{28}F_2N_4O_3$: C, 63.82; H, 6.00; N, 11.91. Found: C, 63.45; H, 5.92; N, 11.76.

^1H NMR (CD_3OD , 300 MHz) δ 7.15 (d, $J = 6.6$ Hz, 2H), 6.90 (m, 4H), 6.46 (s, 1H), 5.12 (s, 1H), 4.57 (m, 1H), 2.28 (s, 6H), 1.69 (s, 6H), 1.45 (d, $J = 7.1$ Hz, 3H).

5

Example 19.




10 MS 479.0 (M+H), 501.2 (M+Na).

Anal Calcd for $C_{23}H_{22}F_4N_4O_3 \cdot 3/2H_2O$: C, 54.65; H, 4.99; N, 11.08. Found: C, 54.95; H, 5.00; N, 10.77.

^1H NMR (CD_3OD , 300 MHz) δ 7.33 (m, 1H), 7.14 (d, $J = 6.0$ Hz, 2H), 6.92 (m, 3H), 6.39 (s, 1H), 5.12 (s, 1H), 4.56 (m, 1H), 1.75 (s, 6H), 1.44 (d, $J = 7.1$ Hz, 3H).

15

Example 20.



20

MS 457.2 (M+H), 478.8 (M+Na).


Anal Calcd for $C_{24}H_{26}F_2N_4O_3 \cdot 1/2H_2O$: C, 61.93; H, 5.85; N, 12.04. Found: C, 61.75; H, 5.84; N, 11.88.

^1H NMR ($CDCl_3$, 300 MHz) δ 11.87 (s, 1H), 7.81 (d, $J = 9.9$ Hz, 1H), 7.18 (m, 3H), 7.08 (m, 3H), 6.83 (m, 1H), 6.11 (s, 1H), 5.07 (s, 1H), 4.53 (m, 1H), 2.81 (d, $J = 5.3$ Hz, 1H), 2.67 (m, 1H), 1.38 (d, $J = 6.6$ Hz, 3H), 1.27 (m, 6H).

25

Example 21.

5




MS 511.0 (M+H), 533.2 (M+Na).

Anal Calcd for $C_{24}H_{23}F_5N_4O_3$: C, 56.47; H, 4.54; N, 10.98. Found: C, 56.14; H, 4.72; N, 10.79.

10 ^1H NMR ($CDCl_3$, 300 MHz) δ 12.18 (s, 1H), 7.97 (d, $J = 9.9$ Hz, 1H), 7.47 (d, $J = 8.2$ Hz, 2H), 7.31 (d, $J = 8.2$ Hz, 2H), 7.03 (d, $J = 6.5$ Hz, 2H), 6.76 (m, 1H), 6.47 (s, 1H), 5.10 (s, 1H), 4.76 (m, 1H), 1.67 (d, $J = 3.9$ Hz, 6H), 1.45 (d, $J = 6.6$ Hz, 3H).

Example 22.

15




MS 491.4 (M+H), 513.4 (M+Na), 529.4 (M+K).

20 Anal Calcd for $C_{27}H_{24}F_5N_4O_3$: C, 66.11; H, 4.93; N, 11.42. Found: C, 65.97; H, 4.91; N, 11.18.

^1H NMR ($CDCl_3$, 300 MHz) δ 11.89 (s(br), 1H), 7.88 (d, $J = 9.3$ Hz, 1H), 7.44 (m, 1H), 7.28 (m, 2H), 7.10 (m, 6H), 6.96 (d, $J = 7.1$ Hz, 2H), 6.64 (m, 2H), 5.09 (s, 1H), 4.82 (m, 1H), 4.07 (m, 2H) 1.48 (d, $J = 6.6$ Hz, 3H).

25


Example 23.

5

MS 414.0 (M+H), 436.0 (M+Na)

^1H NMR (CDCl_3 , 300 MHz) δ 12.08 (s, 1H), 8.74 (d, $J = 9.9$ Hz, 1H), 8.53 (d, $J = 4.4$ Hz, 1H), 7.91 (d, $J = 8.2$ Hz, 1H), 7.80 (m, 1H), 7.42 (m, 1H), 6.86 (d, $J = 7.1$ Hz, 2H), 6.73 (s, 1H), 6.60 (m, 1H), 5.10 (m, 1H). 1.81 (s, 3H), 1.76 (s, 3H), 1.56 (d, $J = 6.6$ Hz, 3H).

10


Example 24.

15 MS 464.0 (M+H), 486.2 (M+Na).

Anal Calcd for $\text{C}_{25}\text{H}_{23}\text{F}_2\text{N}_5\text{O}_2 \cdot 3/4\text{H}_2\text{O}$: C, 62.94; H, 5.18; N, 14.68. Found: C, 63.09; H, 5.05; N, 14.77.

^1H NMR (CDCl_3 , 300 MHz) δ 12.16 (s, 1H), 9.32 (d, $J = 8.8$ Hz, 1H), 9.01 (d, $J = 9.9$ Hz, 1H), 8.48 (d, $J = 5.5$ Hz, 1H), 7.83 (m, 2H), 7.70 (t, $J = 7.7$ Hz, 1H), 7.54 (t, $J = 8.2$ Hz, 1H), 6.86 (d, $J = 6.0$ Hz, 2H), 6.76 (s, 1H), 6.59 (m, 1H), 5.16 (m, 1H), 1.80 (s, 3H), 1.78 (s, 3H), 1.62 (d, $J = 6.6$ Hz, 3H).

20

Example 25.

25


MS 357.2 (M+H).

Anal Calcd for $\text{C}_{20}\text{H}_{28}\text{N}_4\text{O}_2$: C, 67.39; H, 7.92; N, 15.72. Found: C, 67.05; H, 7.65; N, 15.72.

30

^1H NMR (CDCl_3 , 300 MHz) δ 11.95 (s, 1H), 11.87 (s(br), 1H), 7.23 (m, 5H), 6.87 (d, J = 9.3 Hz, 1H), 6.63 (s, 1H), 4.94 (m, 1H), 1.99 (m, 3H), 1.76 (s, 3H), 1.74 (s, 3H), 1.41 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 6.0 Hz, 3H), 0.80 (d, J = 5.5 Hz, 3H).


5 Example 26.



MS 343.1 ($\text{M}+\text{H}$).

^1H NMR (CDCl_3 , 300 MHz) δ 11.86 (s, 1H), 7.23 (m, 5H), 6.60 (m, 2H), 6.63 (s, 1H), 4.93 (m, 1H), 2.19 (m, 2H), 1.75 (s, 3H), 1.74 (s, 3H), 1.50 (m, 2H), 1.40 (d, J = 6.6 Hz, 3H), 0.84 (t, J = 7.7 Hz, 3H).


Example 27.



MS 486.1 ($\text{M}+\text{H}$).





^1H NMR (CDCl_3 , 300 MHz) δ 11.91 (s, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.07 (m, 4H), 6.74 (m, 1H), 6.61 (d, J = 8.8 Hz, 2H), 6.49 (s, 1H), 5.06 (s, 1H), 4.75 (m, 1H), 2.83 (s, 6H), 1.63 (s, 6H), 1.40 (d, J = 6.6 Hz, 3H).

Example 28.



MS 478.1 ($\text{M}+\text{H}$).

^1H NMR (CDCl_3 , 300 MHz) δ 7.22 (m, 4H), 6.57 (s, 1H), 4.86 (m, 1H), 3.78 (s(br), 2H), 2.88 (s, 3H), 1.72 (s, 3H), 1.71 (s, 3H), 1.40 (m, 12H).




2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-[5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide MS 447 (M+H), 470 (M+Na)

MS 447 (M+H), 470 (M+Na)

¹H NMR (CDCl₃, 300 MHz) δ 7.13 (m, 5H), 6.88 (m, 3H), 6.28 (s, 1H), 5.096 (s, 1H), 4.55

5 (m, J = 6.9, 1H), 2.87 (s, 2H), 1.41 (d, j = 6.9 Hz, 3H), 1.283 (s, 6H)


Example 33.



2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-[5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide

MS 447 (M+H), 470 (M+Na)


Example 34.



2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-[5-(1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide

MS 429 (M+H), 452 (M+Na)

Example 35.




2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide

MS 479 (M+H)

^1H NMR (MeOH, 300 MHz) δ 7.11 (m, 2H), 6.81 (m, 3H), 6.43 (s, 1H), 5.09 (s, 1H), 4.54 (m, $J = 7.2$, 1H), 1.67 (s, 6H), 1.41 (d, $j = 7.2$ Hz, 3H)

5 Example 36.




2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl-amino]-N-{5-[1-(4-fluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide

MS 461 (M+H)

10 ^1H NMR (MeOH, 300 MHz) δ 7.27 (m, 2.3), 7.12 (m, 2H), 7.00 (m, 2H), 6.85 (m, 1H), 6.40 (s, 1H), 5.09 (s, 1H), 4.53 (m, 1H), 1.68 (s, 6H), 1.42 (d, $J = 6.9$ Hz, 3H)

Example 37.




15 N-{1-[5-(1,1-Dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-yl]-ethyl}-2-hydroxy-3-methyl-butylamide

MS 387 (M+H)

^1H NMR (DMSO, 300 MHz) δ 7.13 (m, 3H), 6.87 (m, 2H), 6.29 (s, 1H), 4.63 (m, 1H), 3.90 (d, $J = 3.6$ Hz, 1H), 2.87 (s, 2H), 2.11 (m, 1H), 1.98 (d, $J = 3.9$ Hz, 1H), 1.42 (d, $J = 6.9$ Hz, 3H), 1.28 (s, 6H), 1.01 (d, $J = 6.9$ Hz, 3H), 0.86 (d, $J = 6.6$ Hz, 3H)

Example 38.




N-(1-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-ylcarbamoyl}-ethyl)-2-hydroxy-3-methyl-butyramide

MS 409 (M+H)

¹H NMR (DMSO, 300 MHz) δ 6.84 (m, 3H), 6.44 (s, 1H), 4.62 (m, 1H), 3.90 (d, J = 1.5, 1H), 2.1 (m, 1H), 1.67 (s, 6H), 1.43 (d, J = 6.9 Hz, 3H), 1.00 (d, J = 6.9 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H)

Example 39.




2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-[5-(4-phenyl-tetrahydro-pyran-4-yl)]-2H-pyrazol-3-yl]-propionamide

MS 485 (M+H), 506.8 (M+Na)

¹H NMR (MeOH, 300 MHz) δ 7.25 (m, 4H), 7.09 (m, 3H), 6.85 (m, 1H), 6.44 (s, 1H), 5.06 (s, 1H), 4.51 (m, 1H), 3.78 (m, 2H), 3.60 (m, 2H), 2.27 (m, 4H), 1.36 (d, J = 6.9 Hz, 3H)


Example 40.



2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide

MS 479 (M+H)

Example 41.




2-Chloro-N-(1-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-ylcarbamoyl}-ethyl)-benzamide

MS 446.8 (M+H), 468.8 (M+Na), 485 (M+K)

Anal Calcd for C₂₂H₂₁ClF₂N₄O₂: C, 59.13; H, 4.74; N, 12.54 Found: C, 58.88; H, 4.94; N, 12.19

¹H NMR (MeOH, 300 MHz) δ 7.50 (m, 1H), 7.33 (m, 3H), 6.71 (m, 2H), 6.58 (m, 1H), 4.77
5 (m, 1H), 1.62 (s, 6H), 1.47 (d, J = 9 Hz, 3H)

Example 42.




N-(1-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-ylcarbamoyl}-ethyl)-2-
10 trifluoromethyl-benzamide

MS 481 (M+H), 503 (M+Na), 518 (M+K)

Anal Calcd for C₂₃H₂₁F₅N₄O₂: C, 57.50; H, 4.41; N, 11.66 Found: C, 57.20; H, 4.57; N, 11.23

¹H NMR (MeOH, 300 MHz) δ 7.66 (m, 4H), 6.79 (m, 3H), 6.51 (m, 1H), 4.67 (m, 1H), 1.66
15 (s, 6H), 1.46 (d, J = 8.7 Hz, 3H)

Example 43.




N-(1-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-ylcarbamoyl}-ethyl)-3-
20 trifluoromethyl-benzamide

MS 481 (M+H), 503 (M+Na), 518.8 (M+K)

Anal Calcd for C₂₃H₂₁F₅N₄O₂: C, 57.50; H, 4.41; N, 11.66 Found: C, 57.13, H, 4.46; N, 11.41


¹H NMR (MeOH, 300 MHz) δ 8.19 (s, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.80 (d, J = 7.8 Hz,
25 1H) 7.61 (t, J = 7.8 Hz, 1H), 6.752 (m, 3H), 6.43 (s, 1H), 4.72 (m, 1H), 1.64 (s, 6H), 1.52
(d, J = 7.2 Hz, 3H)

Example 44.

N-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-hydroxy-2-(2-trifluoromethyl-phenyl)-acetylamino]-propionamide

MS 511.2 (M+H), 533 (M+Na)


¹H NMR (MeOH, 300 MHz) δ 7.59 (m, 3H), 7.45 (m, 1H), 6.79 (m, 3H), 6.39 (m, 1H), 5.43 (m, 1H), 5.57 (m, 1H), 1.66 (s, 7H), 1.48 (d, J = 6.9 Hz, 3H)

10 **Example 45.**

2-[2-(4-tert-Butyl-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide

MS 499.2 (M+H), 521 (M+Na)


15 ¹H NMR (MeOH, 300 MHz) δ 7.36 (s, 4H), 6.82 (m, 3H), 6.41 (s, 1H), 5.01 (s, 1H), 4.53 (m, 1H), 1.66 (s, 6H), 1.41 (d, J = 6.9 Hz, 3H), 1.28 (s, 9H)

Example 46.


20 2-[2-(4-tert-Butyl-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide

MS 499.2 (M+H), 521 (M+Na)


¹H NMR (MeOH, 300 MHz) δ 7.35 (s, 4H), 6.79 (m, 3H), 6.38 (s, 1H), 5.01 (s, 1H), 5.46 (m, 1H), 1.65 (s, 6H), 1.43 (d, J = 6.9 Hz, 3H), 1.26 (s, 9H)

Example 47.

- 5 2-[2-(3-Chloro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide
MS 477.2 (M+H), 499.0 (M+Na), 514.8 (M+K)
Anal Calcd for C₂₃H₂₃ClF₂N₄O₃: C, 57.92; H, 4.86; N, 11.75 Found: C, 57.75; H, 5.27; N, 11.23
- 10 ¹H NMR (MeOH, 300 MHz) δ 7.47 (s, 1H), 7.37 (m, 1H), 7.27 (m, 2H), 6.78 (m, 3H), 6.42 (s, 1H), 5.04 (s, 1H), 4.51 (m, 1H), 1.65 (s, 6H), 1.40 (d, J = 7.2 Hz, 3H)

Example 48.

- 15 N-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-(2-hydroxy-2-p-tolyl-acetylamino)-propionamide
MS 457.2 (M+H), 479 (M+Na)
¹H NMR (MeOH, 300 MHz) δ 7.30 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 7.8 Hz, 2H), 6.79 (m, 3H), 6.43 (s, 1H), 4.99 (s, 1H), 4.53 (m, 1H), 2.28 (s, 3H), 1.654 (s, 6H), 1.40 (d, J = 6.9 Hz, 3H)
- 20 3H)

Example 49.


- 25 2-[2-(4-Chloro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide

MS 477.0 (M+H), 498.8 (M+Na), 514.8 (M+K)

Anal Calcd for $C_{23}H_{23}ClF_2N_4O_3$: C, 57.92; H, 4.86; N, 11.75 Found: C, 57.70; H, 4.92; N, 11.43

^1H NMR (MeOH, 300 MHz) δ 7.43 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 10.8 Hz, 2H), 6.78 (m, 3H), 6.40 (s, 1H), 5.04 (s, 1H), 4.52 (m, 1H), 1.647 (s, 6H), 1.39 (d, J = 7.2 Hz, 3H)

Example 50.




N-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-hydroxy-2-(4-methoxy-phenyl)-acetylamino]-propionamide

MS 473 (M+H), 495 (M+Na)

Anal Calcd for $C_{24}H_{26}F_2N_4O_4$: C, 61.01; H, 5.55; N, 11.86 Found: C, 61.63; H, 5.25; N, 11.11

^1H NMR (MeOH, 300 MHz) δ 7.32 (m, 2H), 6.83 (m, 5H), 6.45 (s, 1H), 4.98 (s, 1H), 4.51 (m, 1H), 3.75 (s, 3H), 1.66 (s, 6H), 1.41 (d, J = 6.9 Hz, 3H)

Example 51.




N-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-hydroxy-2-(4-trifluoromethyl-phenyl)-acetylamino]-propionamide

MS 511 (M+H), 532.8 (M+Na)

Anal Calcd for $C_{24}H_{23}F_5N_4O_3$: C, 56.47; H, 4.54; N, 10.98 Found: C, 56.12; H, 4.68; N, 10.53

^1H NMR (MeOH, 300 MHz) δ 7.64 (m, 4H), 6.78 (m, 3H), 6.48 (s, 1H), 5.14 (s, 1H), 4.52 (m, 1H), 1.65 (s, 6H), 1.39 (d, J = 6.9 Hz, 3H)


Example 52.

2-[2-(2-Chloro-phenyl)-2-hydroxy-acetyl-amino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide

MS 477 (M+H)

¹H NMR (MeOH, 300 MHz) δ 7.36 (m, 2H), 7.27 (m, 2H), 6.79 (m, 3H), 6.51 (s, 1H), 5.51 (s, 1H), 4.57 (m, 1H), 1.66 (s, 6H), 1.46 (d, J = 6.9 Hz, 3H)


10 **Example 53.**



N-{5-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-(2-hydroxy-cyclohexylamino)-propionamide

MS 406 (M+H)

15 ¹H NMR (CDCl₃, 300 MHz) δ 7.24 (m, 4H), 6.53 (s, 1H), 4.67 (m, 6H), 3.82 (m, 1H), 2.66 (m, 1H), 2.09 (m, 1H), 1.58 (m, 13H), 1.17 (m, 3H)


Example 54.

20 N-(1-{5-[1-(4-Fluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}carbonyl)-2-hydroxy-3-methyl-butyl)-2-hydroxy-3-methyl-butylamide

MS 391 (M+H)

^1H NMR (MeOH, 300 MHz) δ 7.27 (m, 2H), 6.99 (m, 2H), 6.40 (s, 1H), 4.59 (m, 1H), 3.89 (d, $J = 3.6$ Hz, 1H), 2.11 (m, 1H), 1.69 (s, 6H), 1.44 (d, $J = 7.2$ Hz, 3H), 1.02 (d, $J = 6.9$ Hz, 3H), 0.87 (d, $J = 6.9$ Hz, 3H)

5 Example 55.




N-{2-tert-Butyl-5-[1-(4-fluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide

MS 517 (M+H)

10 ^1H NMR (CDCl_3 , 300 MHz) δ 8.18 (s, 1H), 7.24 (m, 4H), 6.96 (m, 2H), 6.91 (m, 2H), 6.77 (m, 1H), 5.97 (s, 1H), 5.01 (s, 1H), 4.49 (m, 1H), 1.61 (s, 6H), 1.56 (s, 9H), 1.38 (d, $J = 7.2$ Hz, 3H)

Example 56.




15

N-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide

MS 535 (M+H)

20 ^1H NMR (CDCl_3 , 300 MHz) δ 8.44 (s, 1H), 7.38 (d, $J = 7.8$ Hz, 1H), 6.93 (m, 2H), 6.75 (m, 3H), 6.54 (m, 1H), 5.96 (s, 1H), 4.97 (s, 1H), 4.64 (s, 1H), 4.52 (m, 1H), 1.58 (s, 6H), 1.51 (s, 9H), 1.23 (d, $J = 6.9$ Hz, 3H)


Example 57.

N-[2-tert-Butyl-5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-yl]-2-[2-(3,5-difluorophenyl)-2-hydroxy-acetylamino]-propionamide

5 MS 513 (M+H)

¹H NMR (CDCl₃, 300 MHz) δ 8.30 (s, 1H), 7.41 (d, J = 7.5 Hz, 1H), 7.14 (m, 3H), 6.97 (m, 4H), 6.72 (m, 1H), 6.01 (s, 1H), 5.00 (s, 1H), 4.52 (m, 1H), 2.85 (s, 2H), 1.52 (s, 9H), 1.38 (d, J = 6.9 Hz, 3H), 1.18 (s, 6H)


10 **Example 58.**



N-[2-tert-Butyl-5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-yl]-2-[2-(3,5-difluorophenyl)-2-hydroxy-acetylamino]-propionamide

MS 513 (M+H)

15 ¹H NMR (CDCl₃, 300 MHz) δ 8.15 (s, 1H), 7.43 (d, J = 7.5 Hz, 1H), 7.13 (m, 3H), 6.96 (m, 4H), 6.70 (m, 1H), 5.96 (s, 1H), 5.04 (s, 1H), 4.61 (m, 1H), 4.32 (m, 1H), 2.81 (s, 2H), 1.44 (d, J = 6.9 Hz, 3H), 1.17 (s, 6H)

Example 58a


20

{1-[2-tert-Butyl-5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-yl]carbamoyl}-ethyl carbamic acid tert-butyl ester

MS 443 (M+H)

¹H NMR (CDCl₃, 300 MHz) δ 7.18 (m, 3H), 6.97 (m, 2H), 6.17 (s, 1H), 4.32 (m, 1H), 2.88 (s, 2H), 1.58 (s, 9H), 1.46 (m, 12H), 1.22 (s, 6H)

5 Example 59.




N-[2-tert-Butyl-5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-yl]-2-phenylacetylaminopropionamide

MS 390 (M+H)

10 ¹H NMR (CDCl₃, 300 MHz) δ 7.40 (m, 5H), 7.16 (m, 3H), 6.94 (m, 3H), 6.25 (s, 1H), 3.77 (s, 2H), 2.86 (s, 2H), 1.29 (s, 9H), 1.21 (s, 6H)

Example 60.




15 N-{1-[2-tert-Butyl-5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-ylcarbamoyl]-ethyl}-butyramide

MS 342 (M+H)

¹H NMR (MeOH, 300 MHz) δ 7.11 (m, 3H), 6.92 (m, 2H), 5.82 (s, 1H), 2.86 (s, 2H), 2.34 (t, J = 6.6 Hz, 2H), 1.71 (m, 2H), 1.57 (s, 9H), 1.22 (s, 6H) 1.02 (t, J = 7.5 Hz, 3H)

20

Example 61.



N-[2-tert-Butyl-5-(4-phenyl-tetrahydro-pyran-4-yl)-2H-pyrazol-3-yl]-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide


MS 541.4 (M+H), 563.4 (M+Na)

Anal Calcd for C₂₉H₃₄N₄F₂O₃: C, 64.43; H, 6.34; N, 10.36 Found: C, 64.20; H, 6.22; N,

5 10.30

¹H NMR (MeOH, 300 MHz) δ 8.43 (s, 1H), 7.24 (m, 5H), 7.09 (m, 1H), 6.91 (m, 2H), 6.70 (m, 1H), 5.91 (s, 1H), 4.90 (s, 1H), 4.78 (s, 1H), 4.42 (m, 1H), 3.73 (m, 4H), 2.38 (m, 2H), 2.12 (m, 3H), 1.51 (s, 9H), 1.20 (d, J = 6 Hz, 3H)

10 Example 62.



N-(1-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}carbonyl)-ethyl)-3-trifluoromethyl-benzamide


MS 537.2 (M+H), 559.2 (M+Na)

15 Anal Calcd for C₂₇H₂₉F₅N₄O₂: C, 60.44; H, 5.45; N, 10.44 Found: C, 60.27; H, 5.26; N, 10.17

¹H NMR (CDCl₃, 300 MHz) δ 8.92 (s, 1H), 8.01 (s, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.89 (d, J = 7.5 Hz, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.39 (t, J = 7.8 Hz, 1H), 6.77 (m, 2H), 6.50 (m, 1H), 5.94 (s, 1H), 5.04 (m, 1H), 1.55 (s, 6H), 1.52 (m, 12H)

20

Example 63.




N-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(4-tert-butyl-phenyl)-2-hydroxy-acetylamino]-propionamide

25 MS 555 (M+H), 577.2 (M+Na)

Anal Calcd for C₃₁H₄₀F₂N₄O₃: C, 67.13; H, 7.27; N, 10.10 Found: C, 67.07; H, 7.28; N, 9.90

^1H NMR (CDCl_3 , 300 MHz) δ 8.61 (s, 1H), 7.32 (m, 3H), 7.22 (m, 2H), 6.82 (m, 2H), 6.54 (m, 1H), 5.98 (s, 1H), 4.95 (d, $J = 3$ Hz, 1H), 4.56 (m, 1H), 3.98 (d, $J = 6$ Hz, 1H), 1.58 (s, 6H), 1.48 (s, 9H), 1.28 (m, 12H)

5 Example 64.



N-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3-chloro-phenyl)-2-hydroxy-acetyl-amino]-propionamide


MS 533.01 (M+H), 555 (M+Na)

10 Anal Calcd for $\text{C}_{27}\text{H}_{31}\text{ClF}_2\text{N}_4\text{O}_3$: C, 60.84; H, 5.86; N, 10.51 Found: C, 60.62; H, 6.03; N, 10.19

^1H NMR (CDCl_3 , 300 MHz) 8.46 (s, 1H), 7.35 (m, 2H), 7.20 (m, 3H), 6.80 (m, 2H), 6.53 (m, 1H), 5.95 (s, 1H), 4.95 (s, 1H), 4.52 (m, 1H), 1.56 (s, 6H), 1.48 (s, 9H), 1.29 (d, $J = 6$ Hz, 3H)

15


Example 65.



2-(2-Cyclohexyl-2-hydroxy-acetyl-amino)-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide

20 MS 449 (M+H), 471 (M+Na)


Anal. Calcd for $\text{C}_{23}\text{H}_{30}\text{F}_2\text{N}_4\text{O}_3$: C, 61.59; H, 6.74; N, 12.49. Found: C, 61.66; H, 6.80; N, 12.28.

Example 66.

N-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(4-fluoro-phenyl)-2-hydroxy-acetylamino]-propionamide

5 MS 461 (M+H), 483 (M+Na)

Anal. Calcd for $C_{23}H_{23}F_3N_4O_3$: C, 60.00; H, 5.03; N, 12.17. Found: C, 60.20; H, 5.38; N, 11.96.

Example 67.


10

N-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-(2-hydroxy-2-phenyl-acetylamino)-propionamide

MS 443 (M+H), 465 (M+Na)

Anal. Calcd for $C_{23}H_{24}F_2N_4O_3$: C, 62.43; H, 5.47; N, 12.66. Found: C, 61.89; H, 5.67; N,


15 12.38.

Example 68.

2-(2-Hydroxy-2-phenyl-acetylamino)-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide

5 MS 407 (M+H), 429 (M+Na)


Anal. Calcd for $C_{23}H_{26}N_4O_3$: C, 67.96; H, 6.44; N, 13.78. Found: C, 66.58; H, 6.70; N, 13.66.

Example 69.

10

2-(2-Cyclohexyl-2-hydroxy-acetylamino)-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide

MS 413 (M+H), 435 (M+Na)


Example 70.

[2-(3,5-Difluoro-phenyl)-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide

MS 463 (M+H), 485 (M+Na)

Anal. Calcd for $C_{23}H_{22}F_4N_4O_2$: C, 59.74; H, 4.80; N, 12.12. Found: C, 59.51; H, 4.88; N, 11.91.

Example 71.




5 2-(2-Cyclohexyl-acetyl-amino)-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide

MS 397 (M+H), 419 (M+Na)

Anal. Calcd for $C_{23}H_{33}N_4O_2$: C, 69.67; H, 8.13; N, 14.13. Found: C, 69.40; H, 8.20; N, 14.01.

10

Example 72.




15 2-(3,5-Difluoro-phenyl)-N-(1-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}carbonyl)-ethyl)-isobutyramide

MS 491 (M+H), 513 (M+Na)

Anal. Calcd for $C_{25}H_{26}F_4N_4O_2$: C, 61.22; H, 5.34; N, 11.42. Found: C, 61.16; H, 5.60; N, 11.19.


20

Example 73.

N-(1-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-ylcarbamoyl}-ethyl)-3-
5 methyl-3-phenylbutanamide

MS 469 (M+H), 491 (M+Na)


Anal. Calcd for $C_{26}H_{30}F_2N_4O_2$: C, 66.65; H, 6.45; N, 11.96. Found: C, 66.31; H, 6.50; N, 11.89.

10 **Example 74.**

(2-Benzo[1,3]dioxol-5-yl-acetylamino)-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-
pyrazol-3-yl}-propionamide

MS 471 (M+H), 493 (M+Na)


15 Anal. Calcd for $C_{24}H_{24}F_2N_4O_4$: C, 61.27; H, 5.14; N, 11.91. Found: C, 60.72; H, 5.48; N, 11.59.

Example 75.

2-[2-(4-Chloro-phenyl)-2-hydroxy-acetylamino]-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide

5 MS 463 (M+Na)

Anal. Calcd for $C_{23}H_{25}ClN_4O_3$: C, 62.65; H, 5.71; N, 12.71. Found: C, 62.38; H, 5.97; N, 12.38.

Example 76.


10

2-[2-(2,3-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide

MS 479 (M+H)

Anal. Calcd for $C_{23}H_{22}F_4N_4O_3$: C, 57.74; H, 4.63; N, 11.71. Found: C, 57.41; H, 4.89; N,

15 11.31.


Example 77.

2-[2-(3,5-Dimethoxy-phenyl)-acetylamino]-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide

MS 451 (M+H), 473 (M+Na)

Anal. Calcd for $C_{25}H_{30}N_4O_4$: C, 66.65; H, 6.71; N, 12.44. Found: C, 66.11; H, 6.62; N, 12.29.


10 **Example 78.**



2-[2-(3,5-Bis-trifluoromethyl-phenyl)-acetylamino]-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide

15 MS 527 (M+H)

Anal. Calcd for $C_{25}H_{24}F_6N_4O_2$: C, 57.03; H, 4.59; N, 10.64. Found: C, 56.82; H, 4.38; N, 10.54.


Example 79.

5 2-(2-Benzo[1,3]dioxol-5-yl-acetylamino)-N-{2-tert-butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide

MS 527 (M+H), 549 (M+Na)

Anal. Calcd for $C_{28}H_{32}F_2N_4O_4$: C, 63.87; H, 6.13; N, 10.64. Found: C, 63.77; H, 6.02; N, 10.53.


10

Example 80.

N-[2-tert-Butyl-5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-2-[2-hydroxy-2-(4-trifluoromethyl-phenyl)-acetylamino]-propionamide

15 MS 531 (M+H), 553 (M+Na)

Anal. Calcd for $C_{28}H_{33}F_3N_4O_3$: C, 63.38; H, 6.27; N, 10.56. Found: C, 62.99; H, 6.56; N, 10.23.

Example 81.


N-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide

5 MS 519 (M+H), 541 (M+Na)

Anal. Calcd for $C_{27}H_{30}F_4N_4O_2$: C, 62.54; H, 5.83; N, 10.80. Found: C, 62.26; H, 5.74; N, 10.44.

Example 82.


10



N-[2-tert-Butyl-5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-2-[2-(4-chloro-phenyl)-2-hydroxy-acetylamino]-propionamide

MS 497 (M+H), 519 (M+Na)


15

Example 83.

N-(1-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-ylcarbamoyl}-ethyl)-3-methyl-3-phenyl-butyramide

MS 525 (M+H), 547 (M+Na)

- 5 Anal. Calcd for $C_{30}H_{38}F_2N_4O_2$: C, 68.68; H, 7.30; N, 10.68. Found: C, 68.37; H, 7.54; N, 10.52.


Example 84.

- 10 N-[2-tert-Butyl-5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-2-(2-cyclohexyl-acetylamino)-propionamide

MS 453 (M+H), 475 (M+Na)

Anal. Calcd for $C_{27}H_{40}N_4O_2$: C, 71.65; H, 8.91; N, 12.38. Found: C, 71.35; H, 8.66; N, 11.81.

15


Example 85.

N-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(2,3-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide

MS 535 (M+H), 557 (M+Na)

Anal. Calcd for $C_{27}H_{30}F_4N_4O_3$: C, 60.67; H, 5.66; N, 10.48. Found: C, 60.27; H, 5.71; N, 10.26.

Example 86.




5 N-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-(2-hydroxy-2-phenyl-acetyl-amino)-propionamide

MS 547 (M+H), 569 (M+Na)

Anal. Calcd for $C_{29}H_{34}F_4N_4O_2$: C, 63.72; H, 6.27; N, 10.25. Found: C, 63.53; H, 6.05; N, 10.40.

10


Example 87.



N-[2-tert-Butyl-5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-2-(2-hydroxy-2-phenyl-acetyl-amino)-propionamide

15 MS 521 (M+Na)


Anal. Calcd for $C_{27}H_{32}F_2N_4O_3$: C, 65.05; H, 6.47; N, 11.24. Found: C, 64.80; H, 6.45; N, 10.88.

Example 88.

N-[2-tert-Butyl-5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-2-(2-cyclohexyl-2-hydroxy-
5 acetylamino)-propionamide

MS 469 (M+H), 491 (M+Na)


Anal. Calcd for C₂₇H₄₀N₄O₃: C, 69.20; H, 8.60; N, 11.96. Found: C, 68.77; H, 8.22; N, 12.04.

10 **Example 88a**

N-(5-Cyclopentyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluorophenyl)-2-hydroxy-acetylamino]-
propionamide.


MS 393 (M+H), MS 415 (M+Na).

15


Example 89.

2-[2-(3,5-Difluorophenyl)-2-hydroxy-acetylamino]-N-[5-(1-methyl-1-phenyl-ethyl)-2H-
20 pyrazol-3-yl]-propionamide.


MS 443 (M+H), MS 465 (M+Na).

Example 90.

5

Example 91.


10

Example 92.

N-{5-[1-(3-Chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl-amino]-propionamide

MS 477.1 (M+H)


20

Example 93.

- 5 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,4-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide
MS 479.1 (M+H)


Example 94.

10



- 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3-fluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide
MS 461.1 (M+H)


15

Example 95.

- 5 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-methyl-1-(3-trifluoromethyl-phenyl)-ethyl]-2H-pyrazol-3-yl}-propionamide
MS 511.1 (M+H)


Example 96.

10




- N-{5-[1-(3,4-Dichloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide
MS 511.0 (M+H)


15

Example 97.

- 5 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3-methoxy-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide
MS 473.2 (M+H)

Example 98.

- 10 (2S)-N-(5-Cyclopropyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluorophenyl)-acetylamino]-propionamide
MS 349 (M+H), 371 (M+Na).


Example 99.

(2S, 2'S)-N-(5-Cyclopropyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluorophenyl)-2-hydroxyacetyl-
amino]-propionamide

MS

¹H NMR (CDCl₃, 300 MHz) δ 12.11 (s, 1H), 8.02 (d, *J* = 9.9 Hz, 1H), 7.16 (d, *J* = 6.1 Hz,
5 2H), 6.79 (m, 1H), 6.20 (s, 1H), 5.18 (s, 1H), 4.80 (m, 1H), 1.75 (m, 1H), 1.41 (d, *J* = 6.6
Hz, 3H), 0.94 (m, 2H), 0.68 (m, 2H).

Example 100.




10

(2S, 2'S)-2-[2-(3,5-Difluorophenyl)-2-hydroxyacetyl- amino]-N-(5-phenethyl-2H-pyrazol-3-
yl)-propionamide

MS 429 (M+H), 451 (M+Na).


15 Example 101.



(2S, 2'S)-N-{5-[1-(4-Chlorophenylsulfanyl)-1-methylethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-
difluorophenyl)-2-hydroxyacetyl- amino]-propionamide


20 MS 509 (M+H), 531 (M+Na).

Anal Calcd for C₂₃H₂₃ClF₂N₄O₃S•H₂O: C, 52.42; H, 4.78; N, 10.63. Found: C, 52.55; H,
4.90; N, 10.40.

Example 102.

(2S, 2'S)-2-Hydroxy-3-methyl-N-{1-[5-(1-methyl-1-phenylethyl)-2H-pyrazol-3-yl]carbonyl}ethyl]-butyramide


MS 373 (M+H).

Example 103.

(2S)-2-Acetylamino-N-[5-(1,1-dimethyl-2-phenylethyl)-2H-pyrazol-3-yl]-propionamide.

MS 330 (M+H), 351 (M+Na).

¹H NMR (DMSO-d₆, 300 MHz) δ 12.07 (s, 1H), 10.23 (s, 1H), 8.05 (d, *J* = 6.6 Hz, 1H), 7.15 (m, 3H), 6.88 (d, *J* = 7.1 Hz, 2H), 6.17 (s, 1H), 4.36 (m, 1H), 2.83 (s, 2H), 1.81 (s, 3H), 1.19 (m, 9H).

Example 104.


(2S)-2-[2'-(3,5-Difluorophenyl)-2'-oxo-acetylamino]-N-[5-(1-methyl-4-phenylethyl)-2H-pyrazol-3-yl]-propionamide.

MS 441 (M+H).

Anal Calcd for C₂₃H₂₂F₂N₄O₃: C, 62.72; H, 5.03; N, 12.72. Found: C, 62.36; H, 5.00; N, 12.41.

^1H NMR (CDCl_3 , 300 MHz) δ 11.63 (s, 1H), 11.06 (s, 1H), 8.27 (d, $J = 9.3$ Hz, 1H), 7.83 (m, 2H), 7.31-7.21 (m, 4H), 7.16-7.05 (m, 2H), 6.70 (s, 1H), 4.90 (m, 1H), 1.74 (s, 6H), 1.53 (d, $J = 7.1$ Hz, 3H).

5 Example 105.




(2S, 2'R)-2-[2'-(3,5-Difluorophenyl)-2'-hydroxyacetyl-amino]-N-[5-(1-methyl-1-phenylethyl)-2H-pyrazol-3-yl]-propionamide.

10 MS 443 (M+H), 465 (M+Na).

Anal Calcd for $\text{C}_{23}\text{H}_{24}\text{F}_2\text{N}_4\text{O}_3 \cdot 0.5 \text{H}_2\text{O}$: C, 61.19; H, 5.58; N, 12.41. Found: C, 61.72; H, 5.54; N, 12.34.

Example 106




15

(2S, 2'S)-2-[2'-(3,5-Difluorophenyl)-2'-hydroxyacetyl-amino]-N-[5-[1-(2,3-difluorophenyl)-1-methylethyl]-2H-pyrazol-3-yl]-propionamide.

MS 479 (M+H), 501 (M+Na).

20 Anal Calcd for $\text{C}_{23}\text{H}_{22}\text{F}_4\text{N}_4\text{O}_3 \cdot 0.75 \text{H}_2\text{O}$: C, 56.15; H, 4.81; N, 11.39. Found: C, 56.23; H, 4.91; N, 11.01.

Example 107


- 5 N-[5-(1-Cyclohexyl-1-methyl-ethyl)-2H-pyrazol-3-yl]-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl-amino]-propionamide


MS 449.2 (M+H), 471.3 (M+Na).

¹H NMR (CD₃OD, 300 MHz) δ 7.09 (m, 2H), 6.87 (m, 1H), 6.32 (s, 1H), 5.08 (s, 1H), 1.40-1.80 (m, 5H), 1.41 (d, *J* = 7.2 Hz, 3H), 1.24 (s, 6H), 0.90-1.35 (m, 6H).

- 10 ¹³C NMR (CD₃OD, 75 MHz) δ 175.1, 173.4, 165.4 (dd, *J* = 12.3, 245.7 Hz), 155.1, 147.0 (t, *J* = 9.5 Hz), 122.1, 111.5 (dd, *J* = 8.3, 17.6 Hz), 104.8 (t, *J* = 25.9 Hz), 96.8, 74.9, 51.1, 50.4, 39.3, 29.8, 28.9, 28.5, 25.8, 19.4.

Example 108. Synthesis of (2S, 2'S)-2-[2'-(3,5-Difluorophenyl)-2'-hydroxyacetyl-amino]-N-[5-(1-methyl-4-phenylpiperidin-4-yl)-2H-pyrazol-3-yl]-propionamide.






(2S)-1-[2-*tert*-Butyl-5-(1-methyl-4-phenylpiperidin-4-yl)-2H-pyrazol-3-ylcarbamoyl]-ethylcarbamic acid benzyl ester (6).

- 5 A solution of 0.67 g (1.3 mmol) of **5** in 10 mL of absolute MeOH was stirred at RT as 0.33 mL of a 37% aq. solution of formaldehyde was added followed by 0.33 g (4.0 mmol) of NaOAc and 0.27 g (4.3 mmol) of NaCNBH₃. After 16 h, the solvent was removed by rotary evaporation and the residue was extracted with water and EtOAc. The organic layer was dried over MgSO₄, filtered and the solvent was removed by rotary evaporation. Purification
- 10 of the material on silica gel using 4% Et₃N-MeOH as eluant afforded 0.41 g (60%) of ester **6** as a clear, colorless glassy solid.


MS 518 (M+H).



- 15 **(2S)-2-Amino-N-[2-*tert*-butyl-5-(1-methyl-4-phenylpiperidin-4-yl)-2H-pyrazol-3-yl]propionamide (7).**

A mixture of 0.36 g (0.7 mmol) of ester **6** and 0.36 g of 10% palladium on carbon in 5.0 mL of absolute EtOH was shaken under 30 psi of H₂. After 16 h, the mixture was filtered through Celite™ and 0.36 g of fresh 10% palladium on carbon was added to the filtrate. The


20 mixture was again shaken under 30 psi of H₂ and this procedure was repeated until consumption of all starting material. The reaction mixture was filtered through Celite™ and the filtrate was concentrated by rotary evaporation. Purification of the material on silica gel using 4% Et₃N-MeOH as eluant afforded 0.14 g (51%) of amine **7** as clear, colorless oil.




(2S, 2'S)-2-[2'-(3,5-Difluorophenyl)-2'-hydroxyacetyl-amino]-N-[5-(1-methyl-4-phenylpiperidin-4-yl)-2H-pyrazol-3-yl]-propionamide.

5 MS 498 (M+H).


Example 109. Synthesis of (2S, 2'S)-N-[5-(1-Cyclopropyl-4-phenylpiperidin-4-yl)-2H-pyrazol-3-yl]-2-[2'-(3,5-difluorophenyl)-2'-hydroxylacetyl-amino]-propionamide





(S)-1-[2-*tert*-Butyl-5-(1-cyclopropyl-4-phenyl-piperidin-4-yl)-2H-pyrazol-3-ylcarbamoyl]-ethylcarbamamic acid benzyl ester (**11**).


- 5 A solution of 1.22 g (2.4 mmol) of **5** in 20 mL of absolute MeOH was stirred at rt as 1.42 g (2.4 mmol) of conc. acetic acid, 1.28 g of 4Å molecular sieves and 2.15 g (12.3 mmol) of ketal **10** were added followed by 0.68 g (10.8 mmol) of NaCNBH₃. The reaction mixture was refluxed for 16 h, cooled to RT, and filtered to remove solids. The filtrate was concentrated by rotary evaporation and extracted with water and EtOAc. The organic layer
- 10 was dried over MgSO₄, filtered and the solvent was removed by rotary evaporation to afford 0.97 g (74%) of **11** as a clear, colorless, glassy solid.



- 15 (2S, 2'S)-N-[5-(1-Cyclopropyl-4-phenylpiperidin-4-yl)-2H-pyrazol-3-yl]-2-[2'-(3,5-difluorophenyl)-2'-hydroxylacetyl-amino]-propionamide.


MS 524 (M+H), 546 (M+Na).

Example 110. Synthesis of N-(5-tert-Butyl-2H-pyrazol-3-yl)-3-[(3,5-difluoro-phenyl)-formyl-amino]-benzamide




5

A solution of 4.0 mmole (1.0 eq.) of 3,5-difluorobenzaldehyde and 4.0 mmole of 2-aminobenzoic acid in 60 mL of MeOH was prepared. While stirring at RT, 8.0 mmole (2.0 eq.) of NaOAc was added followed by 9.0 mmole of NaCNBH₃. The reaction solution was stirred at RT for 1.5 hr and rotary evaporated. The residue was taken up in 30 mL H₂O and 50 mL EtOAc. The layers were separated. The aqueous layer was extracted with EtOAc (2 X 50 mL). The combined organic layers were dried over Na₂SO₄ and vacuum filtered. The filtrate was rotary evaporated and dried under vacuum to give coupled product **5** (78%).



6

A solution of 3.1 mmole (1.0 eq.) of **5** and 3.5 mmole (1.1 eq.) of aminopyrazole in 10 mL of dry pyridine was cooled to -10 °C. To the cooled solution, 3.4 mmole (1.1 eq.) of POCl₃ was added. After stirring for 15 min, the orange reaction mixture was concentrated. The residue was taken up in 30 mL of H₂O, 20 mL of 2 M HCl, and 70 mL of EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc (2 X 70 mL). The combined organic extracts were washed with saturated aqueous NaHCO₃, followed by drying over Na₂SO₄ and vacuum filtering. The filtrate was rotary evaporated. The crude product was flash chromatographed on silica using 20% EtOAc/hexanes as eluant to afford product **6** (25%).



N-(5-tert-Butyl-2H-pyrazol-3-yl)-3-[(3,5-difluoro-phenyl)-formyl-amino]-benzamide


5

A solution of 0.40 mmole of 6 was refluxed in 5 mL of formic acid for 15 min. After cooling to RT, the solution was added dropwise to saturated aqueous NaHCO₃. After ensuring pH 8, the solution was extracted with EtOAc (3 X 70 mL). The combined organic extracts were dried over Na₂SO₄ and vacuum filtered. The filtrate was rotary evaporated.

10 The crude material was flash chromatographed on silica using 75% EtOAc/hexanes as eluant to afford product 7 (57%). This compound does not fall within general Formula I; however, it is a compound of interest because it inhibits β -amyloid peptide release and/or its synthesis. MS 413.2 (M+H), 435.2 (M+Na).

¹H NMR (CDCl₃, 300 MHz) δ 11.07 (s(br), 1H), 10.16 (s, 1H), 8.86 (s, 1H), 8.16 (s, 1H),
15 7.79 (d, J = 7.7 Hz, 1H), 7.36 (m, 1H), 7.19 (m, 1H), 6.65 (m, 4H), 4.96 (s, 2H), 1.29 (s, 9H).

Example 111. N-(5-tert-Butyl-2H-pyrazol-3-yl)-3-(3,5-difluoro-phenylamino)-benzamide




8


20

A suspension of 7.6 mmole (1.0 eq.) of 2-aminobenzoic acid, 8.0 mmole (1.1 eq.) of 3,5-difluorobromobenzene, 0.16 mmole (0.02 eq.) of Pd(OAc)₂, 0.16 mmole (0.02 eq.) of (*S*)-BINAP, and 31.8 mmole (4.0 eq.) of sodium *tert*-butoxide in 20 mL of dry toluene was
25 heated at 90 °C for 15.5 hrs. The mixture was cooled to RT and 40 mL of saturated aqueous NH₄Cl was added. The layers were separated and the aqueous layer was extracted with EtOAc (3 X 70 mL). The combined organic layers were dried over Na₂SO₄ and vacuum

filtered. The filtrate was rotary evaporated. The crude material was flash chromatographed on silica with 75% EtOAc/hexanes as eluant to give coupled product **8** (15%).

**9**

5 A solution of 1.4 mmoles (1.0 eq.) of **8** and 1.5 mmoles (1.1 eq.) of aminopyrazole in 5 mL of dry pyridine was cooled to -10°C . To the cooled solution, 1.5 mmoles (1.1 eq.) of POCl_3 was added. After stirring for 20 min, the orange reaction mixture was concentrated. The residue was taken up in 20 mL of H_2O , 10 mL of 2 M HCl , and 50 mL of EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc (2 X 50 mL). The
10 combined organic extracts were washed with saturated aqueous NaHCO_3 followed by drying over Na_2SO_4 and vacuum filtering. The filtrate was rotary evaporated. The crude product was flash chromatographed on silica using 20% EtOAc/hexanes as eluant to afford product **9** (30%).




15

N-(5-tert-Butyl-2H-pyrazol-3-yl)-3-(3,5-difluoro-phenylamino)-benzamide


Hydrogen chloride gas was bubbled through a solution of 0.29 mmole of **9** in 15 mL of
20 MeOH for 2 min. The reaction solution was refluxed for 5 hrs. The solution was rotary evaporated. The residue was dissolved in 40 mL of saturated aqueous NaHCO_3 and extracted with EtOAc (3 X 50 mL). The combined organic extracts were dried over Na_2SO_4 and vacuum filtered. The filtrate was rotary evaporated. The crude product was flash chromatographed on silica with a step gradient of 50% and 75% EtOAc/hexanes as eluants
25 to afford product 91891 (12%). This

compound does not fall within general Formula I, however, it also inhibits β -amyloid peptide release and/or its synthesis. ^1H NMR (CD_3OD , 300 MHz) δ 7.71 (s(br), 1H), 7.55 (d, $J = 7.7$ Hz, 1H), 7.46 (m, 1H), 7.37 (d, $J = 7.7$ Hz, 1H), 6.67 (d, $J = 7.7$ Hz, 2H), 6.47 (s, 1H), 6.38 (m, 1H), 1.38 (s, 9H).

5 Example 112. Synthesis of Product 14.




13



14

A solution of 1.2 mmole of **13** in 15 mL of TFA was refluxed overnight. After 17 hrs, the solution was cooled to RT and added dropwise to saturated aqueous NaHCO_3 . After ensuring pH 8, the solution was extracted with EtOAc (3 X 70 mL). The combined organic extracts were dried over MgSO_4 and vacuum filtered. The filtrate was rotary evaporated and dried under vacuum to afford the product **14**.




The *n*-butyl isocyanate intermediate was generated by treating 0.96 mmole (1.0 eq.) of 1-aminobutane with 1.9 mmole (2.0 eq.) of 1.93 M phosgene in toluene. The 1-aminobutane was dissolved in 5 mL of CH_2Cl_2 and 5 mL of saturated aqueous NaHCO_3 and cooled to 0°C . The phosgene was added to the methylene chloride layer and stirred vigorously for 10 min. The layers were separated. The organic layer was dried over MgSO_4 and vacuum filtered. The filtrate was rotary evaporated and dried under vacuum to afford *n*-butyl isocyanate.

In a separate flask, a solution of 0.95 mmole (1.0 eq.) of **14**, 1.2 mmole (1.3 eq.) of Et_3N in 5 mL of THF was prepared. A solution of the *n*-butyl isocyanate in 2 mL of CH_2Cl_2 was added and stirred at rt for 35 min. The reaction mixture was rotary evaporated. The crude product was purified on a TLC preparatory plate using 7% MeOH/ CH_2Cl_2 as eluant to give urea product 104228.MS 408.2 ($\text{M}+\text{H}$), 429.8 ($\text{M}+\text{Na}$). ^1H NMR (CDCl_3 , 300 MHz) δ

11.96 (s(br), 1H), 6.80 (d, $J = 7.1$ Hz, 2H), 6.59 (m, 2H), 5.63 (d, $J = 8.2$ Hz, 1H), 4.79 (m, 2H), 3.01 (m, 2H), 1.73 (s, 3H), 1.71 (s, 3H), 1.41 (d, $J = 7.1$ Hz, 3H), 1.33 (m, 2H), 1.21 (m, 2H), 0.82 (t, $J = 7.1$ Hz, 3H).

5

Example 113.

10


(2S)-2-(3,4-Dichlorophenylamino)-N-{5-[1-(3,5-difluorophenyl)-1-methylethyl]-2H-pyrazol-3-yl}-propionamide.

MS 453 (M+H).

Anal Calcd for $C_{21}H_{20}Cl_2F_2N_4O \cdot 0.5 H_2O$: C, 54.56; H, 4.58; N, 12.12. Found: C, 54.76; H, 4.51; N, 11.83.

15


Example 114. Synthesis of 5-(2-[(3,5-Difluorophenyl)acetamino]-2--(isopropylthio)acetamino)-3-tert-butylpyrazole 18



20


25

(3,5-Difluorophenyl)acetamide 1




A solution of 10 g of (3,5-difluorophenyl)acetic acid in 100 mL of tetrahydrofuran was treated with 9.9 g of carbonyldiimidazole. The mixture was stirred at 25 °C for 3 hours then a vigorous stream of anhydrous ammonia was bubbled through the solution for 1 hour. The mixture was stirred for 2 days and then the solvent was evaporated at reduced pressure. The residue was suspended in 100 mL of distilled water. The mixture was filtered and the filtrant was washed with distilled water twice. After drying in a stream of air, the (3,5-difluorophenyl)acetamide was obtained as 8.4 g of an ivory solid. ¹H-NMR (DMSO-d₆): δ 7.51 (broad s, 1H), 7.15 – 6.85 (m, 3H), 3.40 (s, 2H). MS (EI): *m/z* 171. EA Calc'd for C₈H₇NO: C, 56.13; H, 4.13; N, 8.18. Found: C, 56.16; H, 4.05; N, 8.07.

2-[(3,5-Difluorophenyl)acetylamino]-2-hydroxyacetic acid **2**



A mixture of 7.2 g of (3,5-difluorophenyl)acetamide **1** and 4.6 g of glyoxylic acid hydrate in 75 mL of acetone was refluxed 24 hours. The solvent was evaporated and the residue was dissolved in 300 mL of ethyl acetate. This solution was washed with 150 mL of distilled water. The aqueous phase was discarded. The organic phase was extracted with a solution prepared by diluting 50 mL of a saturated aqueous solution of sodium bicarbonate with 150 mL of distilled water. The organic phase was discarded and the aqueous bicarbonate solution was acidified with 80 mL of 1 N aqueous sodium bisulfate solution. The acidified solution was extracted with three successive 125 mL portions of ethyl acetate. The combined organic extracts were washed with brine and then dried over magnesium sulfate. The solution was filtered and the solvent was evaporated to yield 2-[(3,5-difluorophenyl)acetylamino]-2-hydroxyacetic acid as 5.2 g of a white solid. ¹H-NMR (DMSO-d₆): δ 8.95 (d, *J* = 8 Hz, 1H), 7.15 – 6.90 (m, 3H), 5.37 (d, *J* = 8 Hz, 1H), 3.50 (s, 2H). ¹³C-NMR (DMSO-d₆) δ 171.5, 169.4, 162.4 (dd, *J*_{C-F} = 13, 244 Hz), 140.6 (t, *J*_{C-F} = 10 Hz), 112.6 (dd, *J*_{C-F} = 8, 17 Hz), 71.5, 41.7. MS (CI⁺): *m/z* 246. EA Calc'd for C₁₀H₉F₂NO₄: C, 48.98; H, 3.71; N, 5.71. Found: C, 49.02; H, 3.72; N, 5.51.


Methyl 2-[(3,5-difluorophenyl)acetylamino]-2-methoxyacetate **2A**



A 0 °C mixture of 1.0 g of 2-[(3,5-Difluorophenyl)acetylamino]-2-hydroxyacetic acid **2**, 20 mL of methanol, and 6 mL of dichloromethane was treated with 0.3 mL of sulfuric acid.

- 5 The mixture was stirred 2 days at 25 °C. The solvent was evaporated at reduced pressure and the residue was partitioned between distilled water and ethyl acetate. The aqueous phase was washed with ethyl acetate, and the combined organic extracts were washed successively with a saturated aqueous solution of sodium bicarbonate and brine. The solution was dried over magnesium sulfate and filtered. The solvent was evaporated at
- 10 reduced pressure. The residue was chromatographed on silica gel eluting with 30% ethyl acetate in hexanes. Fractions containing the major component of the mixture were combined to yield methyl 2-[(3,5-difluorophenyl)acetylamino]-2-methoxyacetate **2A** as 0.52 g of a white powder. . ¹H-NMR (DMSO-d₆): δ 9.15 (d, *J* = 8.7 Hz, 1H), 7.15 – 6.85 (m, 3H), 5.34 (d, *J* = 8.7 Hz, 1H), 3.69 (s, 3H), 3.60 (s, 3H), 3.24 (s, 2H). . ¹³C-NMR (CDCl₃) δ 169.9, 168.17, 163.0 (dd, *J*_{C-F} = 12.8, 248 Hz), 137.4 (t, *J*_{C-F} = 9 Hz), 112.2 (dd, *J*_{C-F} = 8, 17 Hz), 102.9 (t, *J*_{C-F} = 25 Hz), 78.3, 56.8, 52.8, 42.7. MS (CI⁺): *m/z* 274. . EA Calc'd for C₁₂H₁₃F₂NO₄: C, 52.74; H, 4.81; N, 5.13. Found: C, 52.52; H, 4.87; N, 5.03.
- 15

- 20 2-[(3,5-Difluorophenyl)acetylamino]-2-methoxyacetic acid **3**




- Methyl 2-[(3,5-difluorophenyl)acetylamino]-2-methoxyacetate **2A** (0.4 g) was dissolved in
- 25 10 mL of dioxane and treated with 2.8 mL of a 1.0 N aqueous sodium hydroxide solution. After 1.5 h most of the solvent was removed by evaporation at reduced pressure. The mixture was acidified with an aqueous solution of sodium bisulfate and washed with two successive portions of ether. The combined organic extracts were washed with brine and then dried with magnesium sulfate. The solution was filtered and the solvent was
- 30 evaporated at reduced pressure to yield 2-[(3,5-Difluorophenyl)acetylamino]-2-

methoxyacetic acid **3** as 0.35 g of a white powder. $^1\text{H-NMR}$ (DMSO-d_6): δ 9.06 (d, J = 8.7 Hz, 1H), 7.15 – 6.85 (m, 3H), 5.23 (d, J = 8.7 Hz, 1H), 3.57 (s, 3H), 3.21 (s, 2H).

5-Amino-1,3-di(*tert*-butyl)pyrazole (2363-46) **17**


5



A mixture of 12.5 g of 4,4-dimethyl-3-oxopentanenitrile, 25 g of *tert*-butylhydrazine hydrochloride, and 27.6 g of potassium carbonate in 400 mL of ethanol was refluxed for 24 h. The mixture was cooled to 25 °C and then it was filtered. The solvent was evaporated from the filtrate and the residue was partitioned between ethyl acetate and distilled water. The organic phase was washed with brine and dried (MgSO_4). The solvent was evaporated at reduced pressure and the residue was dissolved in a small volume of ether. The mixture was diluted with an equal volume of hexanes and then the volume of the solution was reduced by one half by evaporation at reduced pressure. The white solid which precipitated was collected by filtration to give 8.7 g of 5-Amino-1,3-di(*tert*-butyl)pyrazole **17**. $^1\text{H-NMR}$ (CDCl_3): δ 5.43 (s, 1H), 1.62 (s, 9H), 1.25 (s, 9H).

20

5-(2-[(3,5-Difluorophenyl)acetylamino]-2-(isopropylthio)acetylamino)-3-*tert*-butylpyrazole **18**



25

ED50 = 5 nM

Phosphorous oxychloride (0.1 mL) was added to a 0 °C solution of 0.3 g of acid **14** and 0.19 g of 5-amino-1,3-di-*tert*-butylpyrazole **17** in 5 mL of pyridine. After 20 min the reaction mixture was poured onto ice. The resulting suspension was washed with ethyl acetate twice. The combined organic extracts were washed with distilled water, a 1 N aqueous solution of sodium bisulfate, and brine. The solution was dried (MgSO_4) and the solvent was evaporated at reduced pressure. The residue, which had solidified during the solvent

evaporation step, was slurried with a small amount of ethyl acetate. The mixture was filtered and the solid thus obtained was dried in a stream of air to give 75 mg of a white solid.


- 5 A 59 mg sample of this material was suspended in formic acid. The reaction flask was then partially immersed in a preheated 115 °C oil bath. After 20 minutes at reflux the solution was cooled to 25 °C. The formic acid was removed by evaporation at reduced pressure. After completely removing the formic acid the residue was dissolved in a few mL of chloroform and the resulting solution was filtered. The chloroform was evaporated from the
 10 filtrate and the residue suspended in *tert*-butyl methyl ether. The suspension was refluxed for 5 min and then it was cooled to 25 °C. It was filtered and the solid thus obtained was dried in a stream of air. 5-(2-[(3,5-Difluorophenyl)acetylamino]-2-(isopropylthio)acetylamino)-3-*tert*-butylpyrazole **18** is obtained as 37 mg of a white powder.

15

- ¹H-NMR (CDCl₃): δ 7.06 (d, *J* = 10 Hz, 1H), 6.9 – 6.7 (m, 3H), 6.54 (s, 1H), 5.99 (d, *J* = 10 Hz, 1H), 3.62 (s, 2H), 3.1 – 3.1 (m, 1H), 1.31 (s, 9H), 1.27 (d, *J* = 5.4 Hz, 3H), 1.23 (d, *J* = 6.6 Hz, 3H). ¹³C-NMR (DMSO-*d*₆) δ 172.4, 168.4, 164.9 (dd, *J*_{C-F} = 13, 245 Hz), 156.0, 147.6, 141.3 (t, *J*_{C-F} = *ca.* 10 Hz), 113.7 (dd, *J*_{C-F} = 7.7, 17 Hz), 103.6 (t, *J*_{C-F} = 26 Hz), 94.7, 56.7, 43.2, 37.0, 32.6, 30.8, 27.6, 24.8, 24.6. MS (CI⁺): *m/z* 447 (M + Na⁺). EA Calc'd for C₂₀H₂₆F₂N₄O₂S · 1.7 H₂O: C, 52.78; H, 6.51; N, 12.31. Found: C, 52.57; H, 6.16; N, 12.18.

25 Example 115.

Synthesis of 5-(2-[(3,5-Difluorophenyl)acetylamino]-2-(2,2,2-(trifluoroethyl)thio)acetylamino)-3-*tert*-butylpyrazole **19**




30

ED50 = 30 nM

This compound was prepared from the acid 2 (Example 114) using a three step procedure analogous to that used for the preparation of 18 (Example 114). One difference is that the amide bond formation was performed using PhOP(O)Cl_2 in place of POCl_3 . After this
 5 amide bond forming step, the intermediate was purified by filtration through silica gel eluting with 20% ethyl acetate in hexane. Compound 19 gave the following analytical data: 48.92% C, 4.59% H, 11.80 %N.

Example 116

10 Synthesis of 5-(2-[(3,5-Difluorophenyl)acetyl]amino)-2-(ethoxyacetyl)amino-3-*tert*-butylpyrazole 20




ED50 = 128 nM

15 A suspension of 0.4 grams of compound 18 (Example 114) in 20 mL of 1 : 1 dichloromethane/ethanol was treated with 0.375 grams of N-bromosuccinimide. After one hour the solution was treated with 1 mL of a saturated aqueous solution of sodium bisulfite. After an additional 5 min, the mixture was partitioned between water and ethyl acetate. The
 20 organic phase was washed with brine and dried with magnesium sulfate. The solvent was evaporated at reduced pressure and the residue was recrystallized from aqueous methanol twice. The resulting solid was dissolved in 20 mL of ethanol and treated with 50 mg of 10% palladium on carbon and 300 mg of sodium acetate. The mixture was agitated under 50 psi hydrogen gas for 14 h. The mixture was filtered through celite™ and then the solvent was
 25 evaporated at reduced pressure. The residue was partitioned between water and ethyl acetate. The organic phase was washed with brine and dried over magnesium sulfate. The solvent was evaporated at reduced pressure. The residue was recrystallized from a mixture of *tert*-butyl methyl ether and hexanes. The product was isolated as a white powder. Analysis gave 56.91%C, 6.11%H, and 14.20%N.

30

Example 117.

Synthesis of 5-(2-[(3,5-Difluorophenyl)acetylamino]-2-(methylthio)acetylamino)-3-*tert*-butylpyrazole **21**



5


ED50 = 16 nM

This compound was prepared from the acid **11** (Example 114) using a three step procedure analogous to that used for the preparation of **18** from **14** (Example 114). Compound **21** gave the following mass spectral data: $m/z = 419.2$ ($M+H$)⁺.

10

Example 118.

15 Monoethyl 2-(*tert*-butoxycarbonylamino)malonate **22**.



A commercial sample of diethyl 2-aminomalonate hydrochloride (7.0 g) was treated with 5.5 mL of triethylamine in a mixture of 50 mL of tetrahydrofuran and 30 mL of dimethylformamide. The resulting mixture was treated with 6.76 grams of di(*tert*-butyl)pyrocarbonate and stirred at 25 °C for 14 hours. The solvent was evaporated at reduced pressure and the residue was partitioned between ethyl acetate and water. The organic phase was washed with a saturated aqueous solution of sodium bicarbonate, a 1 molar solution of sodium bisulfate and then with brine. It was dried over magnesium sulfate and then the solvent was evaporated at reduced pressure. The resulting oil was dissolved in a mixture of 25 mL of ethanol and 28 mL of acetone. The resulting solution was cooled to 0 °C and treated with 26 mL of a 1.0 N aqueous solution of sodium hydroxide. The mixture was allowed to warm to 25 °C and stirred 18 hours. The solvent was evaporated at reduced pressure and the residue was partitioned between ethyl acetate and water. The aqueous


30

phase was acidified with aqueous sodium bisulfate solution and extracted with ethyl acetate. The organic phase was dried (MgSO₄) and the solvent was evaporated to give an oil. The properties of this compound were in good accord with those described previously (*Journal of Medicinal Chemistry* **1982**, 397).

5

Example 119

Synthesis of 1,3-bis(*tert*-butyl)-5-[2-(3,5-difluorophenyl)acetylamino-2-(ethoxycarbonyl)acetylamino]pyrazole **23**.



10

A mixture of 3.0 g of ester **22** (Example 118) and 2.6 grams of aminopyrazole **17** (Example 114) in 50 mL of 0 °C pyridine was treated with 1.2 mL of phosphorus oxychloride. After 1 hour the mixture was poured into 250 mL of ice water. The mixture was filtered and the
15 filtrant was washed with water several times. The solid was dried in a stream of air to give an off white solid.


This material was dissolved in 100 mL of trifluoroacetic acid and stirred for 1.5 hours. The solvent was evaporated and the residue was partitioned between ethyl acetate and an excess
20 of a saturated aqueous solution of sodium bicarbonate. The aqueous phase was washed with ethyl acetate and the combined organic extracts were washed with brine and dried over magnesium sulfate. The solvent was evaporated at reduced pressure. The resulting oil was dissolved in a minimum volume of ethyl acetate and allowed to stand until seed crystals formed. The solvent was evaporated, and the residue was dissolved in a minimum volume
25 of ether. The solution was diluted with a large excess of hexanes and the volume was reduced by evaporation at reduced pressure. The resulting solid was collected by filtration and washed with hexanes.

A solution of 1.0 gram of this solid, 0.43 g of N-methylmorpholine and 0.53 g of HOBt in
30 30 mL of dimethylformamide was treated with 0.75 grams of EDC hydrochloride. After 18 hours the mixture was partitioned between ethyl acetate and water. The aqueous phase was

washed with water twice and the combined organic extracts were washed twice with water, once with a 1 N aqueous solution of sodium bisulfate, once with a saturated aqueous solution of sodium bicarbonate, and finally with brine. The solution was dried over magnesium sulfate and the solvent was evaporated at reduced pressure. Treating the residual oil with ether gave a solid precipitate, which was collected by filtration.

Example 120.

Synthesis of 3- *tert*-butyl-5-[2-(3,5-difluorophenyl)acetyl-amino-2-(ethoxycarbonyl)acetyl-amino]pyrazole **24**.




ED50 = 73 nM

250 mg of compound **23** (Example 119) was refluxed in 3 mL of formic acid for 20 min. The mixture was cooled to 25 °C and diluted with 12 mL of distilled water. The resulting precipitate was collected by filtration and dried in a stream of air. It was suspended in 5 mL of chloroform and filtered. The solvent was evaporated from the filtrate at reduced pressure. The residue was stirred with 5 mL of *tert*-butyl methyl ether for one hour, and then recovered by filtration. The product was obtained as a white powder. Analysis gave 56.84%C, 5.87%H, 13.28%N.

Example 121.

Synthesis of 3- *tert*-butyl-5-[2-(3,5-difluorophenyl)acetyl-amino-2-(pyrrolidinocarbonyl)acetyl-amino]pyrazole **24**.



ED50 = 10,000 nM

0.7 grams of the ester **23** (Example 119) was dissolved in a mixture of 10 mL of ethanol and 10 mL of acetone. The resulting solution was treated with 2.46 mL of 1.0 N aqueous sodium hydroxide solution. After 48 hours the mixture was acidified with aqueous sodium bisulfate solution. It was partitioned between ethyl acetate and water. The aqueous phase
5 was washed with ethyl acetate and the combined organic extracts were washed with brine. The solution was dried over magnesium sulfate and the solvent was evaporated at reduced pressure to give an ivory solid.

A solution 0.3 g of this solid, 0.062 mL of pyrrolidine, and 0.19 gram of HOBt in 15 mL of
10 DMF was treated with 0.14 grams of EDC hydrochloride. After 20 hours the mixture was partitioned between ethyl acetate and water. The aqueous phase was washed with ethyl acetate and the combined organic extracts were washed with aqueous sodium bisulfate, pH 9 phosphate buffer, and brine. The solution was dried over magnesium sulfate and the solvent was evaporated to give a white powder.

15 This powder was refluxed in 1 mL of formic acid for 20 minutes. The solvent was evaporated in a stream of nitrogen. The residue was partitioned between ethyl acetate and water. The aqueous phase was washed with ethyl acetate, and the combined organic extracts were washed with brine. The organic phase was dried over magnesium sulfate, and
20 the solvent was evaporated at reduced pressure. The residual solid was briefly stirred with 1 mL of tert-butyl methyl ether and then filtered. This solid gave the following mass spectral data: $m/z - 448.2 (M+H)^+$.

The following non-limiting formulation examples (Examples 122-131) illustrate representative pharmaceutical compositions of the present invention.

5 **Example 122**

Hard gelatin capsules containing the following ingredients are prepared:

10	Ingredient	Quantity (mg/capsule)
	Active Ingredient	30.0
	Starch	305.0
	Magnesium stearate	5.0

15

The above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.

Example 123

A tablet formula is prepared using the ingredients below:

20

25	Ingredient	Quantity (mg/tablet)
	Active Ingredient	25.0
	Cellulose, microcrystalline	200.0
	Colloidal silicon dioxide	10.0
	Stearic acid	5.0

30

The components are blended and compressed to form tablets, each weighing 240 mg.

Example 124

A dry powder inhaler formulation is prepared containing the following components:

35	Ingredient	Weight %
	Active Ingredient	5
	Lactose	95

40

The active ingredient is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.

Example 125

5 Tablets, each containing 30 mg of active ingredient, are prepared as follows:

Ingredient	Quantity (mg/tablet)
Active Ingredient	30.0 mg
Starch	45.0 mg
Microcrystalline cellulose	35.0 mg
Polyvinylpyrrolidone (as 10% solution in sterile water)	4.0 mg
Sodium carboxymethyl starch	4.5 mg
Magnesium stearate	0.5 mg
Talc	1.0 mg
Total	120 mg

20

The active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50 - 60°C. and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 120 mg.

25

Example 126

30 Capsules, each containing 40 mg of medicament are made as follows:

Ingredient	Quantity (mg/capsule)
Active Ingredient	40.0 mg
Starch	109.0 mg
Magnesium stearate	1.0 mg
Total	150.0 mg

40

The active ingredient, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 150 mg quantities.

Example 127

Suppositories, each containing 25 mg of active ingredient are made as follows:

5	<table><tr><th>Ingredient</th><th>Amount</th></tr><tr><td>Active Ingredient</td><td>25 mg</td></tr><tr><td>Saturated fatty acid glyceride</td><td>2,000 mg</td></tr></table>	Ingredient	Amount	Active Ingredient	25 mg	Saturated fatty acid glyceride	2,000 mg
Ingredient	Amount						
Active Ingredient	25 mg						
Saturated fatty acid glyceride	2,000 mg						

10

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.

15

Example 128

Suspensions, each containing 50 mg of medicament per 5.0 mL dose are made as follows:

20	<table><tr><th>Ingredient</th><th>Amount</th></tr><tr><td>Active Ingredient</td><td>50.0 mg</td></tr><tr><td>Xanthan gum</td><td>4.0 mg</td></tr><tr><td>Sodium carboxymethyl cellulose (11%)</td><td>50.0 mg</td></tr><tr><td>Microcrystalline cellulose (89%)</td><td></td></tr><tr><td>Sucrose</td><td>1.75 g</td></tr><tr><td>Sodium benzoate</td><td>10.0 mg</td></tr><tr><td>Flavor and Color</td><td>q.v.</td></tr><tr><td>Purified water to</td><td>5.0 mL</td></tr></table>	Ingredient	Amount	Active Ingredient	50.0 mg	Xanthan gum	4.0 mg	Sodium carboxymethyl cellulose (11%)	50.0 mg	Microcrystalline cellulose (89%)		Sucrose	1.75 g	Sodium benzoate	10.0 mg	Flavor and Color	q.v.	Purified water to	5.0 mL
Ingredient	Amount																		
Active Ingredient	50.0 mg																		
Xanthan gum	4.0 mg																		
Sodium carboxymethyl cellulose (11%)	50.0 mg																		
Microcrystalline cellulose (89%)																			
Sucrose	1.75 g																		
Sodium benzoate	10.0 mg																		
Flavor and Color	q.v.																		
Purified water to	5.0 mL																		
25																			
30																			

30

The active ingredient, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.

35

Example 129

Ingredient	Quantity (mg/capsule)
Active Ingredient	15.0 mg
Starch	407.0 mg
Magnesium stearate	3.0 mg
Total	425.0 mg

The active ingredient, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 425.0 mg quantities.

Example 130

A subcutaneous formulation may be prepared as follows:

Ingredient	Quantity
Active Ingredient	5.0 mg
Corn Oil	1.0 mL

Example 131

A topical formulation may be prepared as follows:

Ingredient	Quantity
Active Ingredient	1-10 g
Emulsifying Wax	30 g
Liquid Paraffin	20 g
White Soft Paraffin to	100 g

The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The active ingredient is added and stirring is continued until dispersed. The mixture is then cooled until solid.

Example 132. β -amyloid precursor protein accumulation assay

An assay to evaluate the accumulation of $A\beta$ is used to detect potential inhibitors of secretase. The assay uses the N 9 cell line, characterized for expression of exogenous APP by immunoblotting and immunoprecipitation.

- 5 The effect of test compounds on the accumulation of $A\beta$ in the conditioned medium is tested by immunoprecipitation as described in WO 01/19797. Briefly, N 9 cells are grown to confluency in the 6-well plates. Test compounds dissolved in DMSO are added together with the addition of radiolabel. The cells are incubated for 4 h at 37°C in a tissue culture incubator.
- 10 At the end of the incubation period, the conditioned medium is harvested and pre-cleared by the addition of normal mouse serum and of protein A Sepharose, mixed by end-over-end rotation for 30 minutes at 4°C, followed by a brief centrifugation in a microfuge. The supernatant is then harvested and transferred to fresh tubes containing of a monoclonal antibody directed against an internal peptide sequence in $A\beta$ and protein A Sepharose.
- 15 After incubation overnight at 4°C, the samples are washed. The pellet after the last wash is resuspended in SDS sample buffer and boiled for 3 minutes. The supernatant is then fractionated on SDS gels. The gels are dried and exposed to X-ray film or analyzed by phosphorimaging. The resulting image is analyzed for the presence of $A\beta$ polypeptides. The steady-state level of $A\beta$ in the presence of a test compound is compared to wells treated
- 20 with DMSO (1%) alone. A typical test compound is considered active if it blocks $A\beta$ accumulation in the conditioned medium, and has an IC_{50} less than 100 μ M.

Example 133. C-Terminus β -amyloid Precursor Protein Accumulation Assay

- 25 The effect of test compounds on the accumulation of C- terminal fragments is determined by immunoprecipitation of APP and fragments thereof from cell lysates as described in WO 01/19797. N 9 cells are metabolically labeled as above in the presence or absence of test compounds. At the end of the incubation period, the conditioned medium are harvested and cells lysed in buffer. Lysates are precleared with normal rabbit serum and protein A-Sepharose, followed by the addition of BC-1 antiserum and protein A-Sepharose
- 30 for 16 hours at 4°C. The immunoprecipitates are washed bound proteins eluted by boiling in SDS sample buffer and fractionated by Tris/Tricine SDS-PAGE. After exposure to X-ray film or phosphorimager, the resulting images are analyzed for the presence of C-terminal APP fragments. The steady-state level of C-terminal APP fragments is compared to wells

treated with DMSO (1%) alone. A typical test compound is considered active if it stimulates C-terminal fragment accumulation in the cell lysates, and has an IC_{50} less than 100 μ M.

5 **Example 134. A β Immunoprecipitation Assay**

This immunoprecipitation assay as described in WO 01/19797 is specific for γ secretase (i.e., proteolytic activity required to generate the C-terminal end of A β either by direct cleavage or generating a C-terminal extended species which subsequently further proteolyzed). Briefly, N 9 cells are pulse-labeled in the presence of a reported γ secretase inhibitor for 1 h, followed by washing to remove the radiolabel and the inhibitor. The media is replaced and test compounds are added. A β is isolated from the conditioned medium and C-terminal fragments from cell lysates. The test compounds are characterized to determine whether a stabilization of C-terminal fragments is observed and whether A β is generated from these accumulated precursor. A typical test compound is considered active if it prevents the generation of A β out of accumulated C-terminal fragments and has an IC_{50} less than 100 μ M.

Example 135. Cellular Screen for the Detection of Inhibitors of β -Amyloid Production

20 Compounds of Formula I are assayed for their ability to inhibit β -amyloid peptide production in a cell line possessing the Swedish mutation. This screening assay employed cells (K293=human kidney cell line) which were stably transfected with the gene for amyloid precursor protein 751 (APP751) containing the double mutation Lys₆₅₁ Met₆₅₂ to Asn₆₅₁ Leu₆₅₂ (APP751 numbering) in the manner described in WO 94/10569 and Citron *et al* (*Nature*, 360:672-674 (1992)). This mutation is commonly called the Swedish mutation. 25 The cells, designated as "293 751 SWE", are plated in Corning 96-well plates at $1.5-2.5 \times 10^4$ cells per well in Dulbecco's minimal essential media (Sigma, St. Louis, MO.) plus 10% fetal bovine serum. Cell number is important in order to achieve β -amyloid ELISA results within the linear range of the assay (about 0.2 to 2.5 ng per mL).

30 Following overnight incubation at 37°C. in an incubator equilibrated with 10% carbon dioxide, media were removed and replaced with 200 μ L of a compound of formula I (drug) containing media per well for a two hour pretreatment period and cells were incubated as above. Drug stocks were prepared in 100% dimethyl sulfoxide such that at the

final drug concentration used in the treatment, the concentration of dimethyl sulfoxide did not exceed 0.5% and, in fact, usually equaled 0.1%.

At the end of the pretreatment period, the media are again removed and replaced with fresh drug containing media as above and cells are incubated for an additional two
5 hours. After treatment, plates are centrifuged in a Beckman GPR at 1200 rpm for five minutes at room temperature to pellet cellular debris from the conditioned media. From each well, 100 μ L of conditioned media or appropriate dilutions thereof are transferred into an ELISA plate precoated with antibody 266 (*Nature*, 359:325-327 (1992)) against amino acids 13-28 of β -amyloid peptide as described in WO 94/10569 and stored at 4°C overnight. An
10 ELISA assay employing labelled antibody 6C6 (*Nature*, 359:325-327 (1992)) against amino acids 1-16 of β -amyloid peptide is run the next day to measure the amount of β -amyloid peptide produced.

Cytotoxic effects of the compounds are measured by a modification of the method of Hansen, *et al.* (*J. Immun. Meth.*, 119:203-210 (1989)). To the cells remaining in the tissue
15 culture plate is added 25 μ L of a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma, St. Louis, MO.) stock solution (5 mg/mL) to a final concentration of 1 mg/mL. Cells are incubated at 37°C. for one hour, and cellular activity was stopped by the addition of an equal volume of MTT lysis buffer (20% w/v sodium dodecylsulfate in 50% dimethylformamide, pH 4.7). Complete extraction is achieved by overnight shaking at
20 room temperature. The difference in the OD_{562 nm} and the OD_{650 nm} is measured in a Molecular Device's UV_{max} microplate reader as an indicator of the cellular viability.

The results of the β -amyloid peptide ELISA are fit to a standard curve and expressed as ng/mL β -amyloid peptide. In order to normalize for cytotoxicity, these results are divided by the MTT results and expressed as a percentage of the results from a drug free
25 control.

Example 136. In Vivo Suppression of β -Amyloid Release and/or Synthesis

This example illustrates how the compounds of this invention could be tested for in vivo suppression of β -amyloid release and/or synthesis. For these experiments, 3 to 4 month old PDAPP mice are used (Games *et al.*, Nature 373:523-52 (1995)). Depending upon which compound is being tested, the compound is usually formulated at either 5 or 10 mg/ml. Because of the low solubility factors of the compounds, they may be formulated with various vehicles, such as corn oil (Safeway, South San Francisco, CA); 10% EtOH in corn oil (Safeway); 2-hydroxypropyl- β -cyclodextrin (Research Biochemicals International, Natick MA); and carboxy-methyl-cellulose (Sigma Chemical Co., St. Louis, MO).

The mice are dosed subcutaneously with a 26 gauge needle and 3 hours later the animals are euthanized via CO₂ narcosis and blood is taken by cardiac puncture using a 1 cc 25G 5/8" tuberculin syringe/needle coated with solution of 0.5 M EDTA, pH 8.0. The blood is placed in a Becton-Dickinson vacutainer tube containing EDTA and spun down for 15 minutes at 1500 x g at 5°C. The brains of the mice are then removed and the cortex and hippocampus are dissected out and placed on ice.

1. Brain Assay

To prepare hippocampal and cortical tissue for enzyme-linked immunosorbent assays (ELISAs) each brain region is homogenized in 10 volumes of ice cold guanidine buffer (5.0 M guanidine-HCl, 50 mM Tris-HCl, pH 8.0) using a Kontes motorized pestle (Fisher, Pittsburgh Pa.). The homogenates are gently rocked on a rotating platform for three to four hours at room temperature and stored at -20°C. prior to quantitation of β -amyloid.

The brain homogenates are diluted 1:10 with ice-cold casein buffer (0.25% casein, phosphate buffered saline (PBS), 0.05% sodium azide, 20 μ g/ml aprotinin, 5 mM EDTA, pH 8.0, 10 μ g/ml leupeptin), thereby reducing the final concentration of guanidine to 0.5 M, before centrifugation at 16,000 x g for 20 minutes at 4°C. The β -amyloid standards (1-40 or 1-42 amino acids) were prepared such that the final composition equaled 0.5 M guanidine in the presence of 0.1% bovine serum albumin (BSA).

The total β -amyloid sandwich ELISA, quantitating both β -amyloid (aa 1-40) and β -amyloid (aa 1-42) consists of two monoclonal antibodies (mAb) to β -amyloid. The capture antibody, 266, is specific to amino acids 13-28 of β -amyloid. The antibody 3D6, which is specific to amino acids 1-5 of β -amyloid, is biotinylated and served as the reporter

antibody in the assay. The 3D6 biotinylation procedure employs the manufacturer's (Pierce, Rockford IL) protocol for NHS-biotin labeling of immunoglobulins except that 100 mM sodium bicarbonate, pH 8.5 buffer is used. The 3D6 antibody does not recognize secreted amyloid precursor protein (APP) or full-length APP but detects only β -amyloid species
5 with an amino terminal aspartic acid. The assay has a lower limit of sensitivity of about 50 pg/ml (11 pM) and shows no cross-reactivity to the endogenous murine β -amyloid peptide at concentrations up to 1 ng/ml.

The configuration of the sandwich ELISA quantitating the level of β -amyloid (aa 1-42) employs the mAb 21F12 (which recognizes amino acids 33-42 of β -amyloid) as the
10 capture antibody. Biotinylated 3D6 is also the reporter antibody in this assay which has a lower limit of sensitivity of about 125 pg/ml (28 pM).

The 266 and 21F12 capture mAbs are coated at 10 μ g/ml into 96 well immunoassay plates (Costar, Cambridge MA) overnight at room temperature. The plates are then aspirated and blocked with 0.25% human serum albumin in PBS buffer for at least 1 hour at room
15 temperature, then stored desiccated at 4°C. until use. The plates are rehydrated with wash buffer (Tris-buffered saline, 0.05% Tween 20) prior to use. The samples and standards are added to the plates and incubated overnight at 4°C. The plates are washed three times with wash buffer between each step of the assay. The biotinylated 3D6, diluted to 0.5 μ g/ml in casein incubation buffer (0.25% casein, PBS, 0.05% Tween 20, pH 7.4) is incubated in the
20 well for 1 hour at room temperature. Avidin-HRP (Vector, Burlingame CA) diluted 1:4000 in casein incubation buffer is added to the wells for 1 hour at room temperature. The colorimetric substrate, Slow TMB-ELISA (Pierce, Cambridge, MA), is added and allowed to react for 15 minutes, after which the enzymatic reaction is stopped with addition of 2 N H₂SO₄. Reaction product is quantified using a Molecular Devices Vmax (Molecular
25 Devices, Santa Clara, CA) measuring the difference in absorbance at 450 nm and 650 nm.

2. Blood Assay


The EDTA plasma is diluted 1:1 in specimen diluent (0.2 gm/l sodium phosphate.H₂O (monobasic), 2.16 gm/l sodium phosphate.7H₂O (dibasic), 0.5 gm/l
30 thimerosal, 8.5 gm/l sodium chloride, 0.5 ml Triton X-405, 6.0 g/l globulin-free bovine serum albumin; and water). The samples and standards in specimen diluent are assayed

using the total β -amyloid assay (266 capture/3D6 reporter) described above for the brain assay except the specimen diluent is used instead of the casein diluents described.

Although the invention has been described with reference to the presently preferred
5 embodiments, it should be understood that various modifications can be made without departing from the scope of the invention.

What is claimed is:

1. A compound of Formula I:




Formula I

or a pharmaceutically acceptable salt thereof,

wherein R is substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted heteroaryloxy, substituted or unsubstituted alkylamino, substituted or unsubstituted cycloalkylamino, substituted or unsubstituted arylamino, substituted or unsubstituted heteroaryl amino; or

R is



wherein X' and X'' are each independently hydrogen, hydroxy or fluoro, provided when one of X' and X'' is fluoro, the other is not hydroxy; or

X' and X'' together form an oxo group,

Z is selected from the group consisting of alkyl, NH, oxygen,

Sulfur and a bond covalently linking R₁ to -CX'X''-

R₁ is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or

unsubstituted cycloalkenyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl;

R_2 is selected from the group consisting of hydrogen, C_1 - C_4 alkyl, alkylalkoxy, alkylthioalkoxy, $-COOR_{2a}$, and $-COR_{2a}$ wherein R_{2a} is hydrogen, C_1 - C_4 alkyl, cycloalkyl, or heterocycle;

R_3 is H, substituted or unsubstituted, linear-, branched- or cyclo-alkyl or substituted or unsubstituted phenyl;

R_5 is $-Y-R_6$, wherein Y is substituted alkyl, branched alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl; and


R_6 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryloxy, substituted or unsubstituted heteroaryl N-oxide, or substituted or unsubstituted arylthio;

wherein when the alkyl group is substituted, the substituents are 1 to 3 substituents selected from the group consisting of hydroxy, (C_{1-3}) alkoxy, (C_{1-3}) alkylthioxy, halo, acyl, acyloxy, amino, aminoacyl, acylamino, alkoxycarbonyl, carboxyl, cyano, and phenyl optionally substituted with 1 to 2 halo atoms or trifluoromethyl; when the aryl, cycloalkyl, heteroaryl, or heterocyclyl group is substituted, the substituents are 1 to 3 substituents selected from the group consisting of alkyl, alkenyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, alkaryl, alkycycloalkyl, alkycycloalkenyl, alkheteroaryl, alkheterocyclic, alkoxy, aryloxy, halo, nitro, hydroxy, amino, acyl, acyloxy, aminoacyl, acylamino, carboxy, cyano, alkoxycarbonyl, thioalkoxy, and thioaryloxy.

2. The compound of Claim 1, wherein $R = -CR_1X'X''$, X' is H or OH, X'' is H, and R_1 is aryl or substituted aryl.

3. The compound of Claim 2, wherein R_3 is H or t-butyl.

4. The compound of Claim 3, wherein R₂ is methyl.
5. The compound of Claim 4, wherein Y is -CH₂-CH₂-; CH₃-CH<; -C(CH₃)₂CH₂-; CH₃-CH(phenyl)-; >CH(phenyl); or -CH=CH- .
6. The compound of Claim 4, wherein R₁ is 3,5-difluorophenyl.
7. A compound of Formula II:



Formula II

wherein R₁ is aryl, heteroaryl, or cycloalkyl, optionally substituted; X' is H or OH; R₂ is CH₃, R₃ is H, or t-butyl; R₇ is aryl, substituted aryl, or U-Aryl, wherein U is O or CH₂; and R₈ and R₉ are independently H, or alkyl;

wherein when the aryl, cycloalkyl, or heteroaryl group is substituted, the substituents are 1 to 3 substituents selected from the group consisting of alkyl, alkenyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, alkaryl, alkycycloalkyl, alkycycloalkenyl, alkheteroaryl, alkheterocyclic, alkoxy, aryloxy, halo, nitro, hydroxy, amino, acyl, acyloxy, aminoacyl, acylamino, carboxy, cyano, alkoxycarbonyl, thioalkoxy, and thioaryloxy.

8. The compound of Claim 7, wherein R₃ is H and R₈ and R₉ are both methyl.
9. The compound of Claim 7, wherein R₁ is 3,5-difluorophenyl and X' is hydroxyl.
10. The compound of Claim 1 chosen from the group consisting of: N-[2-*tert*-butyl-5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-yl]-2-[2-(3,5-difluorophenyl)-2-

hydroxyacetyl amino]propionamide, 2-[2-(3,5-difluorophenyl)-2-hydroxyacetyl amino]-*N*-[5-(1-methyl-4-phenylpiperidin-4-yl)-2*H*-pyrazol-3-yl]propionamide, 2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-[5-(1-phenyl-cyclopropyl)-2*H*-pyrazol-3-yl]-propionamide, 2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-[5-(1-phenyl-cyclopentyl)-2*H*-pyrazol-3-yl]-propionamide, *N*-{5-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2*H*-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl amino]-propionamide, *N*-{5-[1-(4-nitro-phenyl)-1-methyl-ethyl]-2*H*-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl amino]-propionamide, 2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-[5-(1,1-diphenyl-ethyl)-2*H*-pyrazol-3-yl]-propionamide, 2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-(5-styryl-2*H*-pyrazol-3-yl)-propionamide, *N*-{5-[1-(4-Amino-phenyl)-1-methyl-ethyl]-2*H*-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl amino]-propionamide, *N*-{5-[1-(4-Acetyl amino-phenyl)-1-methyl-ethyl]-2*H*-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl amino]-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-{5-[1-(4-fluoro-phenyl)-cyclopentyl]-2*H*-pyrazol-3-yl}-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-{5-[1-(4-chloro-phenyl)-cyclopentyl]-2*H*-pyrazol-3-yl}-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-[5-(1-phenyl-ethyl)-2*H*-pyrazol-3-yl]-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-[5-(1-phenyl-cyclohexyl)-2*H*-pyrazol-3-yl]-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-{5-[1-(2-fluoro-phenyl)-cyclopentyl]-2*H*-pyrazol-3-yl}-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-{5-[1-(2-fluoro-phenyl)-1-methyl-ethyl]-2*H*-pyrazol-3-yl}-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-{5-[1-(3,5-dimethyl-phenyl)-1-methyl-ethyl]-2*H*-pyrazol-3-yl}-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-{5-[1-(2,4-difluoro-phenyl)-1-methyl-ethyl]-2*H*-pyrazol-3-yl}-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-[5-(2-methyl-2-phenyl-propyl)-2*H*-pyrazol-3-yl]-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl amino]-*N*-{5-[1-(4-trifluoromethyl-phenyl)-1-methyl-ethyl]-2*H*-pyrazol-3-yl}-propionamide, Pyridine-2-carboxylic acid (1-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2*H*-pyrazol-3-yl}carbonyl)-ethyl)-amide, Isoquinoline-1-carboxylic acid (1-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2*H*-pyrazol-3-yl}carbonyl)-ethyl)-amide, 3-


Methyl-N-{1-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-ylcarbamoyl]-ethyl}-
 butyramide, N-{1-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-ylcarbamoyl]-ethyl}-
 butyramide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(4-
 dimethylamino-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, 2-(2-
 Dimethylamino-acetylamino)-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-
 propionamide, 1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid {1-[5-(1-methyl-1-
 phenyl-ethyl)-2H-pyrazol-3-ylcarbamoyl]-ethyl}-amide, N-{5-[1-(4-Chloro-phenyl)-1-
 methyl-ethyl]-2H-pyrazol-3-yl}-2-(2-methylamino-acetylamino)-propionamide, 2-[2-
 (3,5-Difluoro-phenyl)-2(S)-hydroxy-acetylamino]-N-[5-(1,1-dimethyl-2-phenyl-ethyl)-
 2H-pyrazol-3-yl]-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2(R)-hydroxy-acetylamino]-
 N-[5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide, N-{1-[5-(1,1-
 Dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-ylcarbamoyl]-ethyl}-2-hydroxy-3-methyl-
 butyramide, N-(1-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-
 ylcarmoyl}-ethyl)-2-hydroxy-3-methyl-butyramide, 2-[2-(3,5-Difluoro-phenyl)-2-
 hydroxy-acetylamino]-N-[5-(4-phenyl-tetrahydro-pyran-4-yl)-2H-pyrazol-3-yl]-
 propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-
 difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, 2-Chloro-N-(1-{5-[1-
 (3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-ylcarbamoyl}-ethyl)-benzamide, N-
 (1-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-ylcarbamoyl}-ethyl)-2-
 trifluoromethyl-benzamide, N-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-
 3-yl}-2-[2-hydroxy-2-(2-trifluoromethyl-phenyl)-acetylamino]-propionamide, 2-[2-(4-
 tert-Butyl-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-
 ethyl]-2H-pyrazol-3-yl}-propionamide, 2-[2-(4-tert-Butyl-phenyl)-2-hydroxy-
 acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-
 propionamide, 2-[2-(3-Chloro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-difluoro-
 phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, N-{5-[1-(3,5-Difluoro-
 phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-(2-hydroxy-2-p-tolyl-acetylamino)-
 propionamide, 2-[2-(4-Chloro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-difluoro-
 phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, N-{5-[1-(3,5-Difluoro-
 phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-hydroxy-2-(4-methoxy-phenyl)-
 acetylamino]-propionamide, N-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-

3-yl}-2-[2-hydroxy-2-(4-trifluoromethyl-phenyl)-acetylamino]-propionamide, 2-[2-(2-Chloro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, N-{5-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-(2-hydroxy-cyclohexylamino)-propionamide, N-(1-{5-[1-(4-Fluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-ylcarbamoyl}-ethyl)-2-hydroxy-3-methyl-butylamide, N-{2-tert-Butyl-5-[1-(4-fluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, N-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, N-[2-tert-Butyl-5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-yl]-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, N-[2-tert-Butyl-5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-yl]-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, {1-[2-tert-Butyl-5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-ylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester, N-[2-tert-Butyl-5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-yl]-2-phenylacetylamino-propionamide, N-{1-[2-tert-Butyl-5-(1,1-dimethyl-2-phenyl-ethyl)-2H-pyrazol-3-ylcarbamoyl]-ethyl}-butylamide, N-[2-tert-Butyl-5-(4-phenyl-tetrahydro-pyran-4-yl)-2H-pyrazol-3-yl]-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, N-(1-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-ylcarbamoyl}-ethyl)-3-trifluoromethyl-benzamide, N-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(4-tert-butyl-phenyl)-2-hydroxy-acetylamino]-propionamide, N-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3-chloro-phenyl)-2-hydroxy-acetylamino]-propionamide, 2-(2-Cyclohexyl-2-hydroxy-acetylamino)-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, N-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(4-fluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, N-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-(2-hydroxy-2-phenyl-acetylamino)-propionamide, 2-(2-Hydroxy-2-phenyl-acetylamino)-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide, 2-(2-Cyclohexyl-2-hydroxy-acetylamino)-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide, 2-[(3,5-Difluoro-phenyl)-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, 2-(2-Cyclohexyl-acetylamino)-N-[5-(1-methyl-1-phenyl-ethyl)-2H-

pyrazol-3-yl]-propionamide, N-(1-{5-[1-(3,5-Difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}carbamoyl)-ethyl)-3-methyl-3-phenyl-butyramide, (2-Benzo[1,3]dioxol-5-yl-acetylamino)-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, 2-[2-(4-Chloro-phenyl)-2-hydroxy-acetylamino]-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide, 2-[2-(2,3-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, 2-[2-(3,5-dimethoxy-phenyl)-acetylamino]-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide, 2-[2-(3,5-Bis-trifluoromethyl-phenyl)-acetylamino]-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide, 2-(2-Benzo[1,3]dioxol-5-yl-acetylamino)-N-{2-tert-butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, N-[2-tert-Butyl-5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-2-[2-hydroxy-2-(4-trifluoromethyl-phenyl)-acetylamino]-propionamide, N-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide, N-[2-tert-Butyl-5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-2-[2-(4-chloro-phenyl)-2-hydroxy-acetylamino]-propionamide, N-[2-tert-Butyl-5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-2-(2-cyclohexyl-acetylamino)-propionamide, N-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(2,3-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, N-{2-tert-Butyl-5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-(2-hydroxy-2-phenyl-acetylamino)-propionamide N-[2-tert-Butyl-5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-2-(2-hydroxy-2-phenyl-acetylamino)-propionamide, N-[2-tert-Butyl-5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-2-(2-cyclohexyl-2-hydroxy-acetylamino)-propionamide, N-(5-Cyclopentyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, 2-[2-(3,5-Difluorophenyl)-2-hydroxy-acetylamino]-N-[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-yl]-propionamide, (2S)-2-(3,4-Dichlorophenylamino)-N-{5-[1-(3,5-difluorophenyl)-1-methylethyl]-2H-pyrazol-3-yl}-propionamide, 2-(3,5-Difluoro-phenyl)-2-hydroxy-N-{[5-(1-methyl-1-phenyl-ethyl)-2H-pyrazol-3-ylcarbonyl]-thiophen-2-yl-methyl}-acetamide, N-[5-(1-Cyclopropyl-4-phenylpiperidin-4-yl)-2H-pyrazol-3-yl]-2-[2'-(3,5-difluorophenyl)-2'-hydroxylacetylamino]-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-[5-(1-methyl-1-pyridin-3-yl-ethyl)-2H-pyrazol-3-yl]-

propionamide, N-{5-[1-(3-Chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3,4-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3-fluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-methyl-1-(3-trifluoromethyl-phenyl)-ethyl]-2H-pyrazol-3-yl}-propionamide, N-{5-[1-(3,4-Dichloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetylamino]-N-{5-[1-(3-methoxy-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide, N-{5-[1-(4-Chlorophenylsulfanyl)-1-methylethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluorophenyl)-2-hydroxyacetylamino]-propionamide, 2-Hydroxy-3-methyl-N-{1-[5-(1-methyl-1-phenylethyl)-2H-pyrazol-3-yl]carbamoyl}ethyl}-butyramide, 2-Acetylamino-N-[5-(1,1-dimethyl-2-phenylethyl)-2H-pyrazol-3-yl]-propionamide, 2-[2'-(3,5-Difluorophenyl)-2'-oxo-acetylamino]-N-[5-(1-methyl-4-phenylethyl)-2H-pyrazol-3-yl]-propionamide, 2-[2-(3,5-Difluorophenyl)-2-hydroxyacetylamino]-N-[5-(1-methyl-1-phenylethyl)-2H-pyrazol-3-yl]-propionamide, 2-[2-(3,5-Difluorophenyl)-2-hydroxyacetylamino]-N-[5-[1-2,3-difluorophenyl)-1-methylethyl]-2H-pyrazol-3-yl]-propionamide, N-[5-(1-Cyclohexyl-1-methyl-ethyl)-2H-pyrazol-3-yl]-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, 2-(3-Butyl-ureido)-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide and 2-(3,4-Dichlorophenylamino)-N-{5-[1-(3,5-difluorophenyl)-1-methylethyl]-2H-pyrazol-3-yl}-propionamide.

11. A pharmaceutical formulation comprising the compound according to any one of Claims 1-10 and a pharmaceutically acceptable carrier.



Formula (I)